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CHAPTER 1 
INTRODUCTION 
Hypertensive disorders are common in pregnancy and they cause significant 
morbidity and mortality in the fetus, newborn infant and mother (Chesley 
1978). The hypertensive disorders can be divided in pregnancy-induced 
hypertension (PIH), a disease caused by pregnancy, and pre-existing chronic 
hypertension, coinciding with pregnancy. PIH may be accompanied by 
proteinuria, and the clinical entity is then called preeclampsia (PE). 
Preeclampsia may also be superimposed on pre-existent hypertension. 
In addition to the classic signs of hypertension and proteinuria, various 
other signs and symptoms may occur, indicating involvement of many other 
systems (MacGillivray 1983). 
The etiology of PIH is not known although many hypotheses have been developed 
(Chesley 1976, 1978). There is evidence that immunologic factors may be 
involved in the dev~lopment of PIH (Beer 1978, Redman 1981, Dodson 1982). 
Immunologic maladaptation to the fetal allograft may be responsible for 
inhibition of migration of trophoblastic cells into the walls of the spiral 
arteries, resulting in an inadequate physiologic vascular adaptation in women 
developing PIH and/or intrauterine growth retardation (Robertson 1986). In 
man as well as in animals feto-maternal incompatibility of major 
histocompatibility complex (MHC) antigens seems to be favorable for the 
course and outcome of pregnancy (Billington 1964, Palm 1974, Beer 1975, 
Jenkins 1978, Thomas 1985). Incompatibility of non-MHC antigens, however, 
seems unfavorable in this respect ( Palm 1974, Milgram 1977, Croy 1982, 
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Dawson 1982) and may be associated with PIH in man (Need 1983). The question 
as to what kind of pathophysiologic mechanisms are involved in the evolution 
of a condition of primary fetomaternal vascular maladaptation to a disorder 
characterized by hypertension or fetal growth retardation, or both, remains 
unanswered (Robertson 1986). However, there is increasing evidence that a 
disturbance of the physiologic balance between vasodilator prostacyclin and 
vasoconstrictor substances like thromboxane may be involved in this 
maladaptation syndrome, as first suggested by Wallenburg (1979). A shift of 
the balance towards thromboxane may lead to increased vascular resistance in 
various organs, including the uteroplacental bed. This may result in 
hypertension with or without normal organ flow, or in fetal growth 
retardation due to decreased uteroplacental blood flow, or both (Ylikorkala 
1985, Wallenburg 1987). 
To investigate the pathophysiologic mechanisms which play a role in the 
development of PIH an animal model could be of use. Spontaneous PIH does not 
seem to exist in animal pregnancy, although various pregnancy-related 
diseases in animals have been described (Douglas 1971). Therefore, several 
methods were developed in the past to induce hypertension in pregnant 
animals. 
Hypertension has been established in pregnant animals by reducing uterine or 
uteroplacental blood flow before or during pregnancy (Hodari 1967, Cavanagh 
1974, 1985, Abitbol 1976, 1981). A reduced uteroplacental blood flow has 
indeed been found in PIH (Dixon 1963, Trudinger 1985). However, it seems 
likely that placental ischemia is a result of the disease, rather than its 
cause (MacGillivray 1983). Further studies designed to develop animal 
"toxemia" were performed by influencing nutritional or hormonal status during 
pregnancy. These studies have yielded no models with pathophysiologic changes 
comparable to those in human PIH. Only a few studies have been published 
concerning animal models in which PIH is induced on an immunologic basis 
10 
(Seegal 1946, Okuda 1966, Langford 1967). In these experiments animals were 
sensitized against placental tissue before pregnancy, or they received anti-
placenta serum during pregnancy. Hypertension, proteinuria, an increased 
fetal death rate and reduced fetal weight were found in these animals, 
perhaps caused by renal and placental damage. However, these models cannot be 
compared with human PIH, because sensitization against placental antigens as 
a cause of PIH would imply an increased rate in multiparous women, which is 
not the case. A detailed review of various hypotheses of the pathophysiology 
of PIH and of different animal models is presented in chapter 2. 
In view of the possible immunologic mechanism in the pathophysiology of PIH 
we have chosen to study an animal model with different kinds of fetal 
allograft. In order to increase fetomaternal incompatibility female Wistar 
rats were mated with Brown Norway males. Pregnancy results were compared with 
those obtained in Wistar x Wistar couples. Because the Wistar strain is a 
randomly bred strain with good reproductive capability, incompatibility of 
MHC antigens within this strain can be expected to be sufficiently strong to 
warrant a normal outcome of pregnancy. The effect of fetomaternal MHC-antigen 
incompatibility on the course of pregnancy is not expected to change 
markedly when Wistar females are mated with Brown Norway inbred males, but, 
non-MHC antigen incompatibility may be expected to increase. This animal 
experimental design has been used in an attempt to answer the following 
questions: 
- is it possible to develop PIH or a PIH-like syndrome in animals by means of 
an immunologic model ? 
- if so, are the pregnancy results in such a model comparable with those in 
human PIH ? 
- is it possible to modulate the disease by pharmacologic intervention and 
could the model thus be of use in testing medication for treatment of PIH ? 
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The results of maternal variables and of pregnancy outcome are reported in 
chapter 3. The results of morphometric studies of placentas and fetal livers, 
to assess possible placental or fetal ischemia, are reported in chapter 4. In 
order to influence the prostacyclin-thromboxane balance platelet aggregation 
was inhibited during pregnancy by ticlopidjne medication in another group of 
crossbred rats. The results of these experiments are also reported in chapter 
3 and 4. 
In chapter 5 results are discussed against the background of the main 
objectives of this thesis. 
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CHAPTER 2 
PREGNANCY-INDUCED HYPERTENSIVE DISORDERS: A review of 
pathophysiologic mechanisms, experimental approaches in animal 
pregnancy, and spontaneous animal syndromes. 
Pregnancy-Induced Hypertension (PIH) is a worldwide disease, mainly but not 
exclusively occurring in nulliparous women. In most reports the incidence 
varies between 1-10% (Davies 1971). This variation in reported incidences may 
be attributed at least in part to problems concerning definition and 
classification of the disease. These problems are due to the variation in 
clinical presentation of the disease and to its still unknown etiology. There 
is no generally accepted nomenclature, but because of the central role of the 
hypertension we support the term "Pregnancy-Induced Hypertension" (PIH). In 
this review this term will be used for hypertensive disorders in pregnancy 
with or without proteinuria. 
According to a recent classification a diastolic blood pressure of 90 mmHg or 
more in the second half of pregnancy or within 48 hours postpartum in a 
formerly normotensive woman is categorized as PIH. The blood pressure should 
be measured twice with an interval of at least 4 hours at phase 4 of the 
Korotkoff sounds. When PIH is accompanied by proteinuria of 300 mg/1 or more 
it is often called preeclampsia (PE) (Davey 1986). The symptom of edema is 
now generally regarded as too variable and too generally present in 
uncomplicated pregnancy to be useful as part of the definition. 
Apart from the circulation many other systems, such as the coagulation-
platelet system, kallikrein-kinin and renin-angiotensin-aldosterone systems, 
eicosanoid (prostaglandin) and complement systems are involved in the 
pathophysiology of PIH and we may indeed call it a "disease of cascades" 
(MacGillivray 1983). It is unclear whether these mechanisms are primarily or 
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secondarily disturbed, and what the prime mover could be. During normal 
pregnancy impressive physiologic changes take place in the maternal 
organism, possibly induced by immunologic adaptation to the fetal allograft. 
A disturbance of this physiologic adaptation may be responsible for the 
inhibition of migration of trophoblast cells and the inadequate vascular 
adaptation of the spiral arteries, which is found early in pregnancy in women 
destined to develop PIH and/or fetal growth retardation (Robertson 1986). 
Abnormal maternal biochemical adaptation, in particular an imbalance between 
prostacyclin and thromboxane action with dominance of thromboxane, is also 
suspected to be an early feature in this maladaptation syndrome. As a 
consequence, platelet aggregation is stimulated and maternal vessels become 
more sensitive to various vasopressor substances, leading to systemic 
circulatory maladaptation with hypertension and/or local uteroplacental 
circulatory maladaptation which may lead to fetal growth retardation (fig. 1) 
(Wallenburg 1987c). 
A better understanding of the mechanisms of adaptation and maladaptation to 
the fetal allograft and their interrelationships could lead to improvement 
in diagnosis and treatment. In addition to careful clinical observation, 
experimental animal models may be helpful to unravel the pathophysiologic 
mechanisms of PIH. There is considerable doubt as to whether PIH occurs 
spontaneously in animals, it may be a characteristic human disease (Douglas 
1971). On the other hand, it is possible that some pathophysiologic 
mechanisms of PIH occur or can be induced in pregnant animals without leading 
to all the clinical signs and symptoms of the disease observed in man. 
Furthermore, animal models could be useful for the further development of an 
adequate approach to treatment. 
In this review we will first consider some of the etiologic and 
pathophysiologic mechanisms which are thought to be involved in the 
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("MAD") disease, of which PIH is one of the clinical expressions (Wallenburg 
1987c) 
development of PIH in man. We will then discuss spontaneous signs of PIH as 
they occur in animal pregnancy, resembling the disease in man. Finally, 
various reported attempts to induce the disease in animals will be reviewed. 
HYPOTHESES CONCERNING ETIOLOGIC AND PATHOPHYSIOLOGIC MECHANISMS 
IN HUMAN PIH. 
IMMUNOLOGIC FACTORS 
The mechanisms involved in the physiologic protection of allogeneic 
pregnancies by adaptation of the maternal immune system are complex and not 
fully understood. They have been extensively reviewed by several authors 
(Billingham 1981, Beer 1982, Billington 1983, Lala 1983). Because 
fetomaternal maladaptation may be primarily responsible for the development 
of several pregnancy related diseases like PIH (Faulk 1981, Anderson 1982, 
Gille 1982, Wallenburg 1987c) mainstreams of thought concerning the immune 
mechanisms which may be of importance in normal pregnancy will be discussed 
first, followed by an assessment of the possible relationship between 
fetomaternal immune maladaptation and PIH. 
Several authors have reported the presence of specific surface antigens on 
trophoblastic cells in various animal species and in man (Sunderland 1981, 
Wegmann 1981, Billington 1983, Lala 1983). These antigens are in direct 
contact with the maternal immune system and can be detected early in 
pregnancy. Fetomaternal disparity may lead to formation of immune complexes, 
which theoretically may lead to adaptation but also to rejection of the fetal 
allograft, depending on the type of immune complex (Gleicher 1979, 1980). In 
placentae from mice, rats and humans Major Histocompatibility Complex (MHC) 
antigens of class I, but not of class II, were detected on trophoblastic 
cells (Wegmann 1981, Sunderland 1981, Billington 1983, Lala 1983, Billington 
1986). Incompatibility of MHC class I antigens in the absence of class II MHC 
is 
antigens may be responsible for the capacity of trophoblastic cells to induce 
tolerance instead of rejection in the maternal immune system (Wegmann 1981, 
Head 1982). 
Also non-MHC antigens were found on trophoblastic cells in the rat (Ferguson 
1977), the mouse and the human placenta (Billington 1983). Although the role 
of these non-MHC antigens is far from clear, there is some evidence that 
incompatibility may exert a negative effect on the outcome of pregnancy. In 
animal studies an increased occurrence of fetal runting and fetal death has 
been reported following MHC-compatible but non-MHC incompatible crossbreeding 
(Palm 1974, Milgrom 1977). After artificial donor insemination in man, an 
increased rate of PIH was found in women with oligospermic husbands as 
compared to that in women with aspermic husbands. This has been attributed to 
sensitization of the women in the oligospermic group against non-MHC sperm 
specific antigens (Need 1983). 
Immunosuppression in pregnancy is modulated by hormones such as estrogens, 
gonadotrophins, alpha-fetoprotein, placental lactogen and progesterone, of 
which the latter is probably most important (Beer 1982, Siiteri 1982). 
Decidualization is another factor which seems to be involved in 
immunosuppression during pregnancy. It is stimulated by progesterone· as well 
as by fetomaternal antigenic differences (Bell 1983, Lala 1983). Supernatants 
from decidua-associated suppressor cells have been found to inhibit maternal 
interleukin-2 dependent cytotoxity (Daya 1987). Immunoprotection may also be 
achieved by the absorbing capacity of the placenta for immune complexes (Beer 
1982). 
In summary, fetomaternal MHC incompatibility, progesterone production and 
decidualization seem to be important factors with regard to adaptation of the 
mother to the conceptus. On the other hand, non-MHC incompatibility could be 
unfavorable in this process of adaptation. 
The possibility of an immunologic basis underlying the etiology of PIH has 
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been discussed by several authors (J.S.Scott 1976, J.R.Scott 1976, Kitzmiller 
1977, Beer 1978, Redman 1981, Dodson 1982). PIH is predominantly, although 
not exclusively, a disease of nulliparae. Although PIH is a rare occurrence 
after a previous normotensive pregnancy, an increased incidence has been 
observed in pregnancies fo 11 owing a change .of partner (Feeney 1978). A 
decreased incidence of PIH was reported by Stevenson (1976) in consanguineous 
marriages, and an increased incidence was reported in marriages of dissimilar 
race (Alderman 1986). These observations suggest that genetic dissimilarity 
may contribute to the development of PIH. Blood transfusion early in 
pregnancy has been reported to provide some degree of protection against the 
development of PIH (Feeney 1977). The same protection may be obtained through 
pro 1 onged exposure to paterna 1 semen (Marti 1977). Both may be the result of 
sensitization of protective maternal immune responses by foreign (paternal) 
antigens. Increased compatibility of Human Leucocyte Antigen (HLA = MHC 
antigens) between husbands and wives has been found in severe cases of PIH by 
some investigators (Jenkins 1978, Redman 1978a), but could not be confirmed 
by others (Persitz 1983). A reduced production of maternal anti-HLA was 
observed in pregnancies complicated by PIH (Jenkins 1977), but no specific 
HLA antigen was found to be associated with PIH (Redman 1978a, Jenkins 1978, 
Persitz 1983). The role of non-HLA antigens is uncertain, but, as mentioned 
before, exposure to incompatible non-HLA antigen may be involved in the 
development of PIH (Need 1983). Changes in cellular response have also been 
noted in PIH; an impaired maternal lymphocyte response to the fetus was 
described by Jenkins (1978) and Birkeland (1979). However, this 
hyporesponsiveness may be a consequence rather than the cause of the disease 
(Griffin 1979). In patients with PIH natural killer cell activity, which 
could play a role in rejection of the fetus, was reported to be increased 
(Teder 1983) or decreased (Alanen 1982). 
Circulating immune complexes (CIC) may account for the enhanced platelet 
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activation which is found in PIH (Gibson 1982). Platelet-associated IgG and 
IgM and complement were found to be increased in preeclamptic - patients as 
compared with normotensive controls (Massobrio 1985, Rote 1987, Samuels 1987, 
Burrows 1987). An inverse correlation between platelet count and the amount 
of platelet associated immunoglobulins was demonstrated in two studies (Rote 
1987, Burrows 1987); the increased levels of platelet associated 
immunoglobulins may be due to increased ere. Increased levels of ere in 
patients with PIH have been reported by some authors (Schena 1979, Vasquez 
Escobosa 1983, Medcalf 1983, Massobrio 1985), but were not confirmed by 
others (Gleicher 1980, Balasch 1981). Elevated levels of immune complexes 
have also been demonstrated in tissues of patients with PIH such as the skin 
(Houwert-de Jong 1982), the kidney (Petrucco 1974) and the placental vessel 
wall (Kitzmiller 1973). 
Elevated levels of complement have been found in placentas of_women with PIH 
(Sinha 1984), suggesting increased maternal-fetal interaction. Using 
immunofluorescent techniques, complement (e3) deposition was found in the 
spiral arterial walls in the first trimester of pregnancy. High levels of e3 
were found more frequently in primigravidae than in multigravidae, and the 
spiral arteries of primigravidae with high e3 levels often showed vascular 
lesions as described in PIH (Lichtig 1985). The demonstrated absence of the 
physiologic changes in the walls of the spiral arteries of women with PIH 
(Brosens 1972, Gerretsen 1981) could be a result of immunologic reactions 
(Robertson 1986). It is noteworthy that this phenomenon is not only observed 
in patients with PIH, but also in normotensive pregnancies complicated by 
fetal growth retardation (Sheppard 1981). The physiologic changes in the 
spiral arteries during pregnancy are caused by early trophoblast migration, a 
feature common to several animal species and man, The invading trophoblast is 
surrounded by leucocyte infiltration, which suggests an immune response 
(Pijnenborg 1981). 
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PLACENTAL FACTORS 
Some investigators consider uteroplacental ischemia to be a precipitating 
factor in the development of PIH (Page 1972, Speroff 1973, Willems 1977). 
Ischemic villous lesions, placental infarcts, are a feature of PIH; their 
frequency of occurrence and their extent are related to the severity of the 
hypertensive disorder (Wallenburg 1969). Old observations of reduced 
placental blood flow in PIH as measured by injection of radioactive sodium in 
the choriodecidual space (Me Clure Brown 1953, Dixon 1963) are supported by 
recent studies using ultrasound Doppler (Trudinger 1985, Campbell 1986). The 
placental changes in PIH are known to be secondary to ischemia (Wallenburg 
1973), but it is not clear if the reduction of blood flow precedes or follows 
the onset of PIH (Rushton 1984). 
Placental ischemia could explain some of the pregnancy complications 
frequently associated with PIH, such as fetal growth retardation and fetal 
death. However, there is no explanation for the onset of the rise in blood 
pressure and the general vasoconstriction as the result of chronic placental 
ischemia itself, especially not in cases without fetal growth retardation. 
THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM 
Uteroplacental blood flo~ is modulated by several vaso-active substances. In 
particular prostaglandins and the renin-angiotensin system are thought to be 
involved in the pathophysiology of PIH. 
Other vaso-active substances may as well play a role in the modulation of 
uteroplacental blood flow and can also have general vasomotor effects. 
Estrogens have weak vasodilator properties (Wallenburg 1981b), and it is not 
likely that they are directly involved in the pathophysiology of PIH 
(MacGillivray 1983). Catecholamines were found to be increased, decreased or 
unchanged in PIH (Poland 1978, Davey 1981, Tunbridge 1981, Pedersen 1983, 
0ian 1986) and the involvement of catecholamines in PIH is uncertain. 
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Because of its strong vasoconstrictive properties attention has been focussed 
on angiotensin. In normotensive pregnancy all components of the renin-
angiotensin-aldosterone system are elevated (Skinner 1972, Weir 1975, Wilson 
1980, Hsueh 1982, Pedersen 1982, Symonds 1983). In women with PI H plasma 
renin concentration (PRC) and plasma renin activity (PRA) are both lower than 
in normotensive pregnancy (Brown 1966, Weir 1973, Pedersen 1982). .Plasma 
aldosterone concentrations in PIH were also found to be decreased (Weir 
1975, Pedersen 1982, 1983). Angiotensin converting enzyme concentration 
appears to be elevated in PIH (Goldkrand 1986). Reports on angiotensin II 
(AII) levels in PIH are controversial; levels were .found to be decreased 
(Weir 1973) or increased (Symonds 1975, Broughton Pipkin 1981). These 
controversial results may be due to inappropriate measurements because of 
immunologic cross-reactions with AII degradation products (Derkx 1987). 
There is general agreement that the physiologic unresponsiveness to .exogenous 
AII in pregnancy is reduced or even absent in patients with PIH (Abdul-Karim 
1961). The increase in vascular sensitivity to AII begins before the onset of 
clinical signs of PIH (Gant 1973, Oeney 1982). In the nonpregnant state the 
vascular response to endogenous AII is mainly modulated by changes in plasma 
volume and renin activity, but in pregnant women prostaglandins may be of 
more importance in this regard (Worley 1979).In pregnancy the vascular 
refractoriness to AI I. can be abolished by agministration of prostaglandin 
inhibitors like indomethacin or a high dose of aspirin (Everett 1978, 
Jaspers 1981). In the isolated placental cotyledon AII response is attenuated 
by the prostaglandins PGEl' PGD 2 and 6-SPGI 1 , a stable analogue of 
prostacyclin (PGI 2 ) (Glance 1986). 
In pregnancy the vasopressor renin-angiotensin· system seems to be 
counterbalanced by the vasodilator effects· of prostaglandins (Wallenburg 
1981b), and perhaps an imbalance between these two systems could induce 
signs of PIH. In patients with PIH Broughton Pipkin (1981) found higher 
23 
venous levels of AI! in uterine and umbilical blood than in peripheral venous 
blood, which suggest production of AI! in the placenta. A role of the 
placenta in conversion of AI to AI! is supported by in vitro studies of the 
placental cotyledon (Glance 1984). 
There 1s a close relationship between prostaglandin, AI! and renin 
production. PGI
2 
stimulates renin release (Whorton 1977~ which may be 
expected to increase AI!, in the presence of a sufficient amount of renin 
substrate. Angiotensin II itself stimulates PGI 2 in lungs and kidneys as 
shown by Mullane (1980) in vivo in dogs. The in vitro-production of PGE and 
PGI
2 
was enhanced when AI! was injected into the fetal circulation of the 
human placental cotyledon (Glance 1985). 
PROSTAGLANDINS 
Prostaglandins are vasoactive substances, which are thought to play an 
important role in the modulation and regulation of the utero-placental 
circulation (Wallenburg 1981a). During pregnancy there is a physiologic 
increase in the production of prostaglandins E2 and ! 2 which have 
vasodilator action in the utero-placental area (Wallenburg 1981b). 
It has been suggested that, in physiologic pregnancy, vasodilator 
prostaglandin E could counteract the vasoactive effect of AI! (Novy 1980). In 
hypertensive pregnancies prostaglandin E1 and E2 levels in placental tissue 
and urine were found to be reduced as compared with those in normotensive 
pregnancies (Alam 1973, Demers 1976, Robinson 1979, Hillier 1981, Pedersen 
1983). However, it is now known that prostaglandin !2 , prostacyclin, is a 
much more potent vasodilator and the most potent physiologic inhibitor of 
plate1et aggregation (Moncada 1979). In normotensive pregnancy plasma levels 
and urinary excretion of PGI 2 metabolites are elevated (Lewis 1980, Goodman 
1982~ Brash 1983), possibly with a peak during the first (Greer 1985c) or 
second trimester (Bolton 1981). 
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In PIH PGI2 activity in vitro was found to be reduced in maternal, placental 
and umbilical vessels (Bussolino 1980, Remuzzi 1980 a+b). Also in vitro 
production of 6-keto-PGF1a, the stable metabolite of PGI
2
, was shown to be 
reduced in umbilical vessels (Downing 1980, Carreras 1981, Stuart 1981, Dadak 
1982, Makila 1983) and in placental tissue (Walsh 1985 a+b). PGI 2 activity 
was also found to be decreased in amniotic fluid from patients with PIH 
(Bodzenta 1980). The concentration of PGI
2 
metabolites was decreased in 
amniotic fluid (Yl ikorkala 1981b), plasma (Yamaguchi 1985, Greer 1985c) and 
urine (Goodman 1982) obtained from patients with PIH, as compared with 
concentrations in normotensive pregnant women. In addition, a decreased 
prostacyclin biosynthesis was observed preceding the clinical signs of PIH 
(Fitzgerald 1987a). However, these data were not confirmed by all 
investigators. Moodley (1984) found no decrease in 6-keto-PGF1a 
concentration in amniotic fluid from patients with PIH; plasma levels were 
found to be unchanged (Ylikorkala 1981a) or even elevated in PIH (Koull~pis 
1982). flfakila (1984) found the same in vitro placental 6-keto-PGFla 
production in normotensive pregnancy as in PIH. The high plasma levels of 
6-keto-PGF1a , which were found by Yamaguchi (1985), were attributed to 
methodologic errors by some authors (Greer 1985b). In general, however, most 
investigators seem to agree that the vasoconstrictive status in patients with 
PIH is most likely a result of deficient PGI2 action (Briel 1981, Lewis 1983, 
Sitsen 1983, Spitz 1984, Ylikorkala 1985, Lippert 1986). 
Prostacyclin not only counterbalances the vasoconstrictive effects of the 
renin-angiotensin system, but also those of another eicosanoid: 
thromboxane A2 (TXA 2 ). TXA 2 has strong vasoconstrictive and platelet 
aggregating properties and is released mainly by activated platelets in 
nonpregnant as well as in pregnant women (Moncada 1979, Fitzgerald 1987b). 
Data about TXA 2 concentrations, as measured by its stable hydrolysis product 
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TXB2 , in normal pregnancy are conflicting and have been found increased 
(Ylikorkala 1980) or decreased (Greer 1985a). Excretion of major urine 
metabolites of thromboxane increases in pregnancy (Fitzgerald 1987b). In PIH 
in vitro production of TXB
2 
was found to be increased in the placenta (Makila 
1984, Walsh 1985b) or unchanged in umbilical arteries (Makila 1983). Plasma 
levels of TXB
2 
were found to be elevated (Koullapis 1982) or unchanged 
(Yamaguchi 1985) and amniotic fluid levels unchanged (Ylikorkala 1981b, 
Moodley 1984). Increased malondialdehyde formation by platelets, which also 
reflects TXA 2 production, was found in pregnancies complicated by fetal 
growth retardation with or without hypertension (Wallenburg 1982). 
It may be concluded that published data on PGI
2 
and TXA
2 
production or 
concentrations are disparate. Perhaps the functional balance between PGI 2 and 
TXA
2 
may be more important than-their actual concentrations; when the 
balance shifts in favor of TXA 2, hypertension may be the result. Disturbance 
of the placental PGI
2
/TXA
2 
balance could lead to local vasoconstriction, 
enhanced platelet aggregation and thrombosis, thus leading to placental 
ischemia and infarction (Wallenburg 1981a). Such a shift between PGI 2 and 
TXA
2 
was demonstrated by measurements of the in vitro production of PGI 2 
and TXA 2 metabolites in placental tissue (Makila 1984, Walsh 1985b). A 
reduced ratio of in vitro P~I 2 over TXA 2 production appeared to be associated 
with decreased placental intervillous blood flow (~akila 1986). Indirect 
evidence that a shift in the balance of PGI 2/TXA2 may be involved in the 
development of PIH, with or without fetal growth retardation, is based on the 
prevention of PIH in women with an increased vascular sensitivity to 
exogenous AII (Wallenburg 1986) and of fetal growth retardation in women at 
risk (Wallenburg 1987d) by treatment with low doses of aspirin during 
pregnancy. A pathologically increased sensitivity of the vasculature to AI.I 
is reversed by low dose aspirin medication (Wallenburg 1987a). These effects 
are explained by the fact that a low dose of aspirin suppresses TXA 2 
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synthesis with minimal effects on PGI2 synthesis, and thus restores the 
dominance of PGI
2
• 
Dietary factors can interfere with prostaglandin metabolism. Although vitamin 
E deficiency in animals has shown to reduce PGI production (Karpen 1981, 
Spitz 1983), there is as yet no indication that vitamin E deficiency is 
involved in the pathogenesis or pathophysiology of PIH in man (Entman 1984). 
Prostaglandin metabolism can also be manipulated by the use of essential 
fatty acids. It has been shown in pregnant patients that vascular sensitivity 
to AII can be reduced by means of a diet containing primrose oil, which 
contains a substantial amount of linoleic acid, a precursor of arachidonic 
acid (O'Brien 1983). In clinically observed patients with PIH a slight, but 
not significant, improvement of blood pressure was found following 
administration of linoleic acid (Morrison 1984). Eicosapentanoic acid (EPA) 
and its precursor linolenic acid inhibit platelet aggregation, because of 
transformation into TXA 3 , which does not interfere with platelet aggregation, 
and into the potent antiaggregating agent PGI 3 (Dyerberg 1978). In male 
volunteers using an EPA enriched diet, prolonged bleeding times, decreased 
TXA 2 and increased PGI 3 production were found. In addition, the systolic 
blood pressure decreased as well as the blood pressure response to 
noradrenaline and (not significantly) AII administration (Lorenz 1983). There 
is, however, no evidence that an absolute or relative lack of essential fatty 
acids is involved in the pathogenesis of PIH. 
THE COAGULATION-PLATELET SYSTEM 
In normal pregnancy the coagulation system is in an activated state with 
raised levels of nearly all coagulation factors (Stirling 1984, Wallenburg 
1987b). Some investigators have proposed that thrombin-dependent disseminated 
intravascular coagulation (DIC) could be involved in the pathophysiology or 
even pathogenesis of PIH. According to Page (1972) DIC could be attributed in 
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PIH to an accelerated spill of trophoblastic elements into the maternal 
circulation, due to placental ischemia. In patients with PIH 20 times more 
trophoblastic elements were found in the uterine vein at cesarean section 
thdn in normotensive women (Jaameri 1965). After eclampsia McKay (1953) found 
fibrin thrombi in several organs, which he attributed to DIC. He compared 
eclampsia to the general Shwartzman phenomenon, perhaps triggered by 
degradation products from decidua or placenta. Although Sheehan and Lynch 
(1973) also found fibrin thrombi after eclampsia, this was, in their opinion, 
not caused by DIC, but the result of ischemia due to vasospasm. In women with 
PIH an increase in the factor VIII R Ag/VIIIC ratio as compared with that in 
normotensive pregnancy was reported by several authors (Redman 1977b, Fournie 
1981, Scholtes 1983). Although this can be the ~esult of thrombin mediated 
coagulation, it is more likely that it is caused by increased vascular 
endothelial damage or release of platelet factor VIII, since the ratio is 
predominantly increased because of an elevated factor VIII R: Ag (Fournie 
1981, Scholtes 1983). Other coagulation factors, as measured directly or 
indirectly, do not show changes suggestive of marked consumption in most 
cases of PIH (Howie 1971, Condie 1976, Gibson 1982, Wallenburg 1987b, Burrows 
1987). 
The turnover of 125!-labelled fibrinogen appeared to be increased in 
patients with PIH in comparison with normotensive pregnancies (Kuijpers 
1982). A thrombin-mediated mechanism was suggested because of the return of 
the fibrinogen turnover to normal during low-dose heparin medication. An 
increased 125!-turnover, which returned to normal after low-dose heparin, was 
also found in normotensive women during bedrest of at least one week 
(Kuijpers 1982). This finding could, at least in part, explain differences in 
coagulation patterns between normotensive and hypertensive patients, since 
most coagulation studies in hypertensive pregnant patients have been 
performed under conditions of bedrest. Increased thrombin activation in 
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patients with PIH has also been suggested on the basis of increased levels 
of fibrinopeptide A (Douglas 1982), but the elevation of fibrinopeptide A was 
not confirmed in later studies (Wallmo 1984, Burrows 1987). The results of 
soluble fibrin monomer measurements (cryofibrinogen or protamine 
sulphate/ethanol gel precipitation assays) are variable, but increased levels 
were found in some of these studies (Gibson 1982). Soluble fibrinogen/ fibrin 
monomer complexes as measured by chromatography were found to be elevated in 
selected patients with severe preeclampsia (McKillop 1976, 1977, Edgar 1977, 
Beller 1979). Evidence of increased fibrinolysis has been found by several 
authors with measurement of fibrinogen/fibrin degradation products (FOP) and 
fragment E in advanced cases of PE (Henderson 1970, Bonnar 1971, Howie 1971, 
Gordon 1976). Other investigators, however, could not find increased FOP 
levels, even not in eclampsia (Pritchard 1976, Dunlop 1978). 
Direct measurements of plasminogen and indirect measurements of plasminogen 
activation by the euglobulin lysis time appeared to be variable and did not 
result in consistent differences between normotensive pregnancies and PIH/PE 
(Gibson 1982, Wallenburg 1987b). Decreased levels of the physiologic clotting 
inhibitor antithrombin III were found in patients with PIH and were 
associated with placental infarction and poor fetal outcome (Weinel' 1982, 
Weenink 1983 ). 
Because the severity of PIH and the presence or absence of fetal growth 
retardation, which may be associated with coagulation disorders, is often not 
mentioned, it is difficult to compare the results of these studies and to 
draw conclusions. Increased thrombin-dependent coagulation may be a feature 
in some women with severe PIH, but DIC appears to be an exception, even in 
eclampsia (Gibson 1982, Wallenburg 1987b). 
In patients with PIH the average platelet count appears to be reduced as 
compared with that in normal pregnancy (Bonnar 1971, Howie 1971, Dunlop 1978, 
Boneu 1980, Giles 1981). A fall in platelet concentration was reported to be 
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an early feature of the disease (Redman 1978b) and may also be present in 
mild cases of PIH (Dunlop 1978, Giles 1981, O'Brien 1986). Platelet life span 
seems to be reduced in PIH (Rakoczi 1979, Boneu 1980), in particular when PIH 
occurs in combination with fetal growth retardation (Wallenburg 1982). 
Increased platelet activation as assessed by S-thromboglobulin levels 
(Redman 1977a, Boneu 1980, Douglas 1982) and a reduced platelet aggregation 
in vitro in response to various agents (Wigham 1978, Kelton 1985) was found 
in patients with PIH. 
Although thrombocytopenia may be a result of thrombin-dependent coagulation, 
the majority of patients, most of them with mild PIH, have no signs of 
intravascular coagulation, as discussed previously. For that reason it is 
more likely that platelet activation and consumption are thrombin-
independent, and caused by an abnormal platelet-vessel wall interaction in 
the non-endothelialized spiral arteries in the presence of an imbalance of 
PGI 2 /TXA 2 (Wallenburg 1987b). Increased plasma levels of fibronectin, a 
suggested marker for endothelial damage, were reported in patients with PIH 
(Saleh 1987). The increase was even found before the onset of clinical signs 
of PIH (Lazarchik 1986). The vascular endothelial injury in PIH may be caused 
by vasospasm or by immune complexes (Saleh 1987). The occurrence of a direct 
effect of immune complexes on platelets in patients with PIH, leading to 
increased platelet activation and consumption has also been suggested (Bern 
1981, Gibson 1982, Medcalf 1983, Massobrio 1985, Rote 1987, Samuels 1987, 
Burrows 1987). 
It can be concluded that fetomaternal immunologic maladaptation may be 
responsible for the decreased trophoblast invasion of spiral arteries early 
in pregnancy in women destined to develop PIH and/or fetal growth 
retardation. The disturbed balance of PGI2 /TXA 2 action which seems to be 
present in PIH with/without growth retardation can possibly be attributed to 
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immunologic fetomaternal maladaptation, perhaps by direct uteroplacental 
endothelial damage and decreased PGI
2 
production or by increased platelet 
activation and TXA 2 production. The shift in PGI 2 /TXA2 balance could lead to 
an impaired uteroplacental function and placental ischemia, a process which 
may aggrevate the effect of the unbalanced PGI2 /TXA 2 ratio. Meanwhile an 
imbalance between prostaglandin action and the renin-angiotensin system may 
lead to the increased vascular resistance which is a characteristic feature 
of PIH. 
II SPONTANEOUS PIH-LIKE SYNDROMES IN ANIMALS 
Some of the signs and complications of PIH have also been described to occur 
spontaneously in pregnant animals, although usually without hypertension 
(Douglas 1971, Seidl 1979). Complications such as neurologic signs and liver 
and/or kidney lesions, described in the milk-fever syndrome and after 
starvation in several animal species, are not pathognomonic of PIH in man. A 
syndrome with an increased frequency of fetal death, proteinuria and 
hemorrhagic lesions in uterus, placenta, liver and kidneys was described in 
pregnant guinea pigs with aortic hypoplasia. However, in this syndrome blood 
pressure appeared to be lower than in healthy pregnant guinea pigs (Seidl 
1979). 
In non-human primates pregnancy-related convulsions were described in several 
parous chimpanzees, one primigravid chimpanzee, two multiparous orang-utangs, 
one Stuhlmann's monkey and one rhesus monkey (Chez 1975). The disease process 
was lethal in most cases. In the case of the primigravid chimpanzee 
generalized edema and glomerular capillary endothelial swelling were found 
(Stout 1969). 
A placenta with a large number of infarcts, excessive fibrinoid and atherosis 
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of decidual vessels was described following an apparently uncomplicated 
pregnancy in a Patas monkey, which had delivered a normal size stillborn 
fetus (Gille 1977). In a colony of 98 Patas ~onkeys edema and proteinuria was 
observed in 6 animals (Palmer 1979). In only 2 of them blood pressure was 
recorded and appeared to be elevated when compared with that in 15 normal 
pregnant animals. However, 64 of 98 pregnant animals (3 of 6 affected 
animals) received the carcinogenic agents ethylnitrosurea or 
diethylnitrosamine, and from the data it is not clear whether or not the 
hypertensive animals were among them. Another observation was made by Baird 
(1981), who found convulsions and edema in a 9-year-old parous gorilla. 
Spontaneous delivery resulted in the birth of a live infant 3 weeks after the 
"eclamptic" seizure. The placenta was smaller than normal and showed 
infarcts. 
Microscopically syncytial knots and hyaline degeneration were seen. From the 
data presented above we must conclude that there is no convincing evidence 
that PIH occurs spontaneously in animals, not even in nonhuman primates. 
III ANIMAL EXPERIMENTS 
Various experiments have been performed in an attempt to induce hypertensive 
syndromes in pregnant animals. A suitable animal model of PIH must meet 
several requirements. 
a) The model should allow investigation of major signs of PIH such as 
hypertension and proteinuria. 
b) The model should allow investigations of additional signs, such as 
thrombocytopenia, liver and kidney lesions, or impaired fetoplacental 
circulation. 
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c) Results in experimentally manipulated pregnant animals should always be 
compared with those obtained in nonpregnant, normal pregnant or sham-
operated pregnant animals. 
Experimental approaches that could be found in the literature will be 
assessed against the background of these requirements. Many approaches have 
involved experimental uteroplacental ischemia, but administration of hormones 
and vasoactive substances, dietary manipulation, and immunologic approaches 
have also been used. Because the pathophysiologic pathway of PIH in man 
appears to develop some time before the onset of clinical symptoms, we 
consider chronic experiments in animals to be most relevant, although acute 
experiments, involving special effects of the disease, may also provide 
valuable data. In this review animal models with renal hypertension will not 
be discussed because the pathophysiologic mechanisms which lead to 
hypertension are not related to pregnancy. 
UTEROPLACENTAL ISCHEMIA 
Uteroplacental ischemia has been experimentally induced by reduction of 
uteroplacental blood flow at several levels: the placental level, the level 
of the uterine and ovarian arteries, and the level of the abdominal aorta 
below the renal arteries, in order to prevent direct effects on the renal 
blood flow. In most experiments the reduction of uteroplacental blood 
flow 
The 
acute 
was obtained by mechanical means. 
first experiments involving uteroplacental ischemia were of the 
type. Impairment of the uteroplacental circulation was obtained by 
clamping the aorta below the level of the renal arteries, by clamping the 
uterine arteries, by dissection of the ovarian arteries, and by distension of 
the uterine cavity by a balloon. In all of these models a sudden rise in 
blood pressure was observed, which returned to normal after normalization of 
the circulation. In nonpregnant controls blood pressure did not change 
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(Ogden 1940, van Bouwdijk Bastiaanse 1950, Gyonggyossy 1958). 
Another method to induce placental ischemia consisted of placement of z-
sutures through the placentae in pregnant rabbits (Berger 1963, 1964). A rise 
in blood pressure was observed within 25-45 minutes after placing the Z-
sutures, followed by a period of time during which blood pressure remained 
constant or decreased slowly. After 18 hours renal arteriograms showed a 
constriction of the renal arteries and arterioles. The same results were' 
obtained in nephrectomized rabbits, but not in rabbits with Z-sutures placed 
through the uterine wall only. Blood from a nephrectomized rabbit drawn after 
placement of a placental Z-suture evoked an increase in blood pressure in a 
nonpregnant recipient (Berger 1963). 
In a second paper Berger (1964) reported the results of transfer of plasma 
from Z-sutured hypertensive nephrectomized pregnant rabbits to normal 
pregnant rabbits. Most of these rabbits, which were observed for 20 to 72 
hours, developed hypertension and proteinuria. Vasoconstriction as measured 
by arteriography was found in all an.imals, first observed in the renal and 
later in the uterine and ovarian arteries; the placentae became ischemic. 
According to this paper (Berger 1964) an irreversible vicious circle could 
be established experimentally, with prolonged hypertension and placental 
ischemia. This effect could also be established in nephrectomized pregnant 
rabbits, but only slightly in nonpregnant rabbits. The humoral factor was 
also found in plasma of pregnant animals after ligation of one common iliacal 
artery. Induction of placental ischemia by Ali infusions also resulted in a 
vicious circle of prolonged or increased hypertension, vasoconstriction 
and increasing placental ischemia (Berger 1964). These results have never 
been confirmed by other investigators. Smith (1966) and Bregulla (1977) 
failed to obtain hypertension in pregnant rabbits by placing Z-sutures 
through the site of placentation. Wardle (1973) found that Z-sutures in the 
placentae of pregnant rabbits led to severe shock in most animals which 
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aborted soon because of abruptio placentae. Increased proteinuria, increased 
fibrinogen turnover and a decrease in the concentrations of fibrinogen a~d 
platelets were found, perhaps resulting from an increased inflow of placental 
thromboplastin, in particular into the lungs. Mild hypertension was found 
several days after the operation in 3 of 12 animals only. 
Douglas (1967) produced chronic uterine and placental ischemia by wrapping 
the uterine horns of rats and rabbits with cellophane before pregnancy. In 
treated rats blood pressure rose slightly during pregnancy, but significantly 
after pregnancy as compared with a control group. The amounts of proteinuria 
did not differ from those in the control group. Fetal death occurred in 90% 
of cases with placental ischemia. In rabbits there was an increase in 
proteinuria after birth, but no change .in blood pressure. 
Experimental subacute or chronic placental ischemia was induced in pregnant 
dogs by partly occluding the uterine arteries by means of clips together with 
complete ligation of the ovarian arteries 10-15 days before term (Kumar 
1962). A rise in blood pressure was observed to occur after 2 or 3 days, but 
it returned to normal after 6 days. Placental blood flow as measured by 
clearance of radioactive sodium was reduced to 50-75% of its baseline value, 
but it also returned to normal within 7 days, presumably as a result of the 
development of a collateral circulation .. Eight animals were operated again on 
the third and seventh day after the first operation, and the uterine arteries 
were ligated completely, one per operation. Three dogs developed 
hypertension, which persisted after delivery, and five delivered prematurely. 
When animals were operated three times, proteinuria occurred which persisted 
until one week after delivery. No blood ~ressure rise was observed in 
nonpregnant or sham-operated dogs. No histologic studies were done (Kumar 
1962). 
In nonpregnant dogs Hodari and Hodgkinson (1967, 1967) ligated the ovarian 
arteries completely and the uterine arteries partly by placing teflon bands 
35 
around them. Arterial blood pressure was recorded in the femoral artery and 
arteriograms were made in banded and nonbanded animals, before pregnancy and 
after they had become pregnant. Arterial blood pressure in nonbanded pregnant 
and in nonpregnant dogs (banded or nonbanded) was similar, but in banded 
pregnant dogs in which the normally occurring distension of the uterine 
arteries was prevented by the teflon bands an increase in blood pressure 
occurred at as early as 3 weeks' gestation, with a gradual rise throughout 
the remainder of pregnancy. One month post partum blood pressure had returned 
to normal. Proteinuria was more often found in banded than in nonbanded 
pregnant dogs. Arteriograms showed a reduction of the diameter of uterine 
arteries in banded animals, although this was in part compensated for by 
extensive collateral circulation. Fetal and placental weights tended to be 
lower in the banded dogs, although the differences were not significant. 
Histopathologic investigations were not reported and sham-operations 
were not done. 
A similar procedure was performed in guinea pigs (Golden 1980). Of 6 animals 
which were bred after one week, two aborted. In pregnancy there was a slight 
fall in blood pressure in normal animals but an increase in both systolic and 
diastolic blood pressure in banded animals. 
not alter blood pressure in nonpregnant 
Banding the uterine arteries did 
animals. Proteinuria was only 
observed in the banded pregnant group. In banded pregnant animals creatinine 
levels increased, and the kidneys showed deposition of protein-like material 
in the tubules and in the glomeruli, which appeared to be swollen and 
hypercellular. Fetuses of banded animals were smaller, but the placentae did 
not differ from those obtained from normal animals. There were no sham-
operated animals. 
In an experiment with banding of the uterine a.rteries in nonpregnant rats and 
rabbits, with or without ligation of the ovarian arteries, Bregulla (1977) 
failed to obtain hypertension in these animals after they had become pregnant. 
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Uterine arterial banding experiments have also been performed in nonhuman 
primates. In baboons, the uterine arteries were partially occluded and the 
ovarian arteries transected; the animals were bred afterwards. The results 
were compared with those obtained in normal pregnant and in sham-operated 
animals (Cavanagh 1972, 1974, 1977). In banded pregnant animals hypertension, 
proteinuria, a decrease in renal blood flow and an increase in renal and 
peripheral resistance were found to occur in the course of pregnancy. 
Hemoglobin values did not differ, 
were higher than those in normal 
but uric acid levels in the ischemic group 
pregnant baboons. Although coagulation 
'studies showed no abnormalities, immunofluorescent staining for fibrin or 
fibrinogen in glomeruli of hypertensive animals was positive. The histologic 
changes in the kidneys varied from slight to lesions indistinguishable from 
those seen in human preeclampsia. These lesions were also found in a group of 
animals banded during pregnancy. Birthweights are not given. These important 
observations have not been confirmed by other investigators. In the rhesus 
monkey, banding of the uterine arteries before pregnancy resulted in a 
reduced number of spiral artery entries into the intervillous space and an 
increase in fetal loss, but no hypertension or proteinuria was observed 
(Misenhimer 1970). 
Abitbol (1976a, 1976c, 1977b, 1981) produced experimental "toxemia" in 
rabbits, dogs and monkeys by constricting the aorta during pregnancy, just 
below the level of the renal arteries. The degree of stricture appeared to be 
critical. When it was too loose, no effects were seen and when it was too 
tight it resulted in placental separation, fetal death and/or paralysis of 
the hind legs. In general, the diameter of the aorta had to be reduced to 1/3 
or 1/4 of its original size. Sham-operated and nonoperated pregnant and 
nonpregnant animals served as controls. In treated rabbits the average 
systolic blood pressure was markedly raised. About 40% of the ischemic group 
delivered prematurely and in about 50% one or more fetuses were macerated. 
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The average weight of fetuses of comparable length of gestation was 
decreased. Kidney lesions similar to those observed in PIH in man, such as 
mesangial proliferation, focal thickening of the glomerular basement 
membrane, swelling of endothelial cells and subendothelial depositions 
probably of fibrinogen were found in several animals. Focal necrosis and 
subcapsular hemorrhage was observed in the liver of some animals (Abitbol 
1976a). In placentae, syncytial degeneration and syncytial knots, acute and 
older infarcts were seen in cases of "severe toxemia". Mild lesions, such as 
congestion of capillaries and sometimes small infarcts, were seen in rabbits 
which did not develop all the clinical signs and in which ischemia had lasted 
only a few days (Abitbol 1976b). 
In female dogs of mixed breed, blood pressure and blood flow in the abdominal 
aorta were measured 1-3 weeks after placement of an aortic stricture below 
the renal artery (Abitbol 1976c). Values were compared with those obtained in 
a group of dogs in which the blood pressure was measured immediately before 
and after constriction, and with values obtained in sham-operated dogs. 
Because of hemorrhage ali dogs, but one, had to be sacrificed at the end of 
this measurement. Immediately after placement of the stricture there was a 
significant drop in blood flow and pressure in the abdominal aorta below the 
constriction, but no change in the thoracic aorta. When measured 1-3 weeks 
after the operation, a significant rise in systolic and diastolic blood 
pressure as compared with normal pregnant and sham-operated pregnant dogs was 
found in the thoracic aorta in 9 out of 14 ischemic pregnant animals, and 
blood flow in the abdominal aorta was decreased. Marked proteinuria was 
demonstrated in 3 of 14 dogs. Birthweights are not given. Kidney, liver and 
placental lesions, as described in the ischemic pregnant rabbit, were also 
seen in the ischemic pregnant dogs, and were shown to be related to the 
duration of ischemia (Abitbol 1976c). Blood flow changes in the abdominal 
aorta were only observed after a constriction of more than 50%. When the 
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stricture was removed after 10 days, blood pressure below became equal to 
blood pressure above the removed stricture, and hypertensive ischemic dogs 
remained hypertensive, although they were only observed for a couple of hours 
(Abitbol 1977b). Coagulation studies in ischemic pregnant dogs revealed a 
fall in the concentration of platelets and fibrinogen as compared with normal 
pregnant dogs, and iri some cases FOP's were detected (Abitbol 1978). In a 
later study, the same investigators placed a vascular occluder and a flow 
transducer around the abdominal aorta, which made it easier to produce a 
continuously monitored constriction. Hypertension and marked proteinuria were 
observed in about half the number of 21 ischemic pregnant dogs. Fetal outcome 
is not mentioned. Histologic lesions were as described above, and more severe 
in proteinuric than in nonproteinuric animals (Abitbol 1981). 
Finally, the same investigators produced an aortic constriction in pregnant 
monkeys (Macaca Mulatta) by means of a silk suture, reducing the aortic 
diameter 3 or 4 times (Abitbol 1977a). One sham-operated pregnant animal, one 
nonoperated pregnant animal and one nonpregnant animal served as controls. 
Blood pressure changes, proteinuria, kidney-, liver-, and placenta changes 
were similar to those observed in other experimental animals, as described 
above, and comparable to those observed in human PIH. Again, the effects on 
the fetus are not presented. 
Banding of the aorta below the level of the renal arteries has also been 
performed in pregnant baboons (Cavanagh 1985). Animals were operated at 100 
days' gestation, and aortic blood flow below the constriction was reduced by 
55% to 60%. Results were compared with those obtained in sham-operated 
animals. Hypertension occurred near term, and proteinuria and increased renal 
vascular resistance were found. Light and electron-microscopic changes in 
kidney biopsies were similar to those described in human PIH. The number of 
platelets was slightly decreased and uric acid levels increased, although to 
a lesser extent near term. Fetal and placental weights, and amniotic fluid 
39 
volumes were lower in hypertensive than in normotensive baboons, but maternal 
plasma volumes were equal. 
In a recent study, aortic constriction below the renal artery level in 
pregnant rabbits resulted in hypertension, proteinuria, thrombocytopenia and 
hypovolemia when compared with nonoperated nonpregnant, as well as with sham-
operated pregnant and nonpregnant animals (Losonczy 1986-87). Increased 
arterial norepinephrine levels and a positive correlation between the 
arterial norepinephrine concentration and blood pressure were observed in 
pregnant animals with aortic constriction, and uterine venous All 
concentration appeared to be elevated. An increased vascular response to 
exogenous norepinephrine or All was also a feature in treated pregnant 
rabbits. Uterine venous plasma prostanoids (PGE 2 , 6-keto-PGF1a , PGFm, TXB2 ) 
were all elevated in animals with aortic constriction as compared with the 
levels in sham-operated pregnant and nonpregnant animals, but arterial 
plasma prostanoid levels were not different between groups. However, when 
compared with the nonoperated nonpregnant animals, the levels of 
6-keto-PGF1a, PGFm and TXB
2 
were not significantly different. Histologic 
examination revealed focal placental necrosis in about half of the fetuses, 
and fibrin depositions in maternal glomeruli as shown by 
immunofluorescence. No light microscopic lesions were observed in kidneys or 
livers of animals with aortic constriction~ Increased occurrence of fetal 
death and decreased birthweights were observed in rabbits with aortic 
constriction (Losonczy 1986-87). 
In conclusion, several experiments in which the investigators attempted to 
induce chronic placental ischemia resulted in hypertension, proteinuria, 
lesions in several maternal organs, and sometimes fetal growth retardation or 
fetal death (table 1). The best documented pathologic changes were reported 
following experimental chronic placental ischemia induced by banding of the 
aorta during pregnancy, or by banding of the uterine arteries combined with 
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dissection of the ovarian arteries before or during pregnancy. 
studies of Cavanagh (1974, 1985), Abitbol (1976a, 1976b, 1977, 
Only the 
1981) and 
Losonczy (1986-87} meet most of the criteria for a suitable animal model as 
stated before. The failure of some investigators to obtain similar results in 
apparently identical experiments may be due to the kind of animals used in 
their experiments, or to failure to obtain a critical grade of ischemia 
necessary to induce the syndrome. The syndrome in animals induced by 
placental ischemia resembles that observed in human PIH with (severe) fetal 
growth retardation. However, this does not necessarily mean that 
uteroplacental ischemia is primarily responsible for the development of PIH. 
The observation of increased levels of vasodilating prostanoids in placental 
ischemic rabbits is at variance with· findings in human PIH, and may be an 
indication of another pathophysiologic mechanism. 
STEROID HORMONES 
Because of the impressive changes in hormonal production in pregnancy, with 
their possible effects on blood pressure and fluid retention, the role of 
hormones in the etiology and pathogenesis of PIH has been subject of various 
investigations (MacGillivray 1983}. Animal experiments have been performed in 
which hormones were administered in an attempt to induce a PIH-like syndrome; 
the experiments will be briefly discussed. 
In pregnant rats 5 mg of progesterone i.m. daily resulted in a rise in 
systolic blood pressure. The animals also developed proteinuria and liver and 
kidney lesions when pregnancy went on to near term. The placentas showed 
degeneration of Langhans' and syncytial cells, and focal hemorrhage. No 
lesions were found in organs of nonpregnant control animals (Symeonidis 
1950). The occurrence of maternal and fetal death with histologic features of 
DIC was described by Stamler in pregnant rats following daily intramuscular 
injection of 10 mg progesterone, in particular when parturition was delayed 
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_;,. TABLE 1 N 
Investigator animal species experiment acute/chronic hypertension proteinuria fetus PA DIC 
and number 
Ogden et al. 5 dogs 1 cat clamping Aa.ut. acute yes not reported 
1940 ligation Aa.ov. 
v.Bouwdijk 
Bastiaanse 
etal.1950 6 dogs ditto acute yes not reported 
Gyi:ingy6'ssi 
et a l . 1958 6 dogs, 11 cats distension ut.cavity acute yes not reported 
Berger et al. 7 rabbits Z-sutures placenta (sub)acute yes not reported 
1963 3 nephrectom. 
Smith et al. 6 rabbits ditto acute no not reported 
1966 
Wardle et al. 16 rabbits ditto subacute 3 animals yes abortion a,b 
1973 mild hypert. in most 
animals 
Bregull a 15 rabbits ditto subacute no 
et al. 1977 
Berger et al. 7 rabbits plasma transfer 
1964 after Z-sutures pl. subacute yes yes increased 
4 rabbits pharmacal. induced f. death 
plac. ischemia 
Douglas et al.30 rats wrapping uterine chronic after pregn. after pregn. f. death 
1967 4 rabbits horns before pregn. no no f. death 
Kumar 1962 10 {3) dogs dissection Aa.ov. subacute yes yes increased 
(repeated) partly chronic f. death 
occlusion Aa.ut. 
during pregn. 
Hodari 1967 20 dogs banding Aa.ut. chronic yes yes decreased 
dissection Aa.ov. f.weight? 
before pregn. 
Golden et al. 6 guinea pigs ditto chronic yes yes decreased + 
1980 f. weight 
Bregull a 20 rats banding Aa.ut. chronic no 
et a 1. 1977 7 rabbits with/without dissection 
Aa.ov. before pregn. 
Misenhimer 6 rhesus monkeys banding Aa.ut. chronic no no increased 
et al. 1970 before pregn. f. death 
Cavanagh 10 baboons banding Aa.ut. chronic yes yes + b 
et al. 1974 dissection Aa.ov. 
before pregn. 
3 baboons ditto during pregn. 
Abitbol et al. 51 rabbits banding abd. aorta chronic yes yes decreased + b 
1976 during pregn. f.weight, 
f. death 
Abitbol et al. 14 dogs ditto chronic yes yes + a,b 
1976 
Abitbol 1981 21 dogs 
Abitbol et al. 10 monkeys ditto chronic yes yes + b 
1977 
Cavanagh et al. 9 baboons ditto chronic yes yes decreased + b 
1985 f. weight 
Losonczy et al.21 rabbits ditto chronic yes yes decreased b 
1986-87 f.weight, 
f. death 
PA + = histologic lesions comparable to those found in PIH 
DIG a = laboratory findings compatible with DIC 
b = histologic findings compatible with coagulation 
Aa.ut. = uterine arteries 
-!'> Aa.ov. = ovarian arteries 
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for several days (Stamler 1961, 1971, 1977). In these experiments blood 
pressure was not measured. The lesions described in all these experiments may 
well have been caused by the toxic effects of the very high doses of 
progesterone, although the results obtained by Symeonidis and Stamler were 
not confirmed by Hester (1953), who also treated pregnant rats with 5-10 mg 
progesterone daily. 
Adrenocortical hormones may be involved in the pathogenesis of hypertension 
and of the development of edema through retention of salt and water. The 
latter sign, however, cannot be considered characteristic of PIH since it is 
also found in a high proportion of normotensive pregnant women (Davey 1986). 
Parker (1980) found no significant differences between the production of 
desoxycorticosterone (DOCA) in normal pregnancy and in pregnancies complicated 
by PIH. A syndrome with signs resembling those in severe PIH was induced in 
uni-nephrectomized nonpregnant rats. The rats were made hypertensive by the 
administration of desoxycorticosteroneacetate (DOCA) and a high intake of 
sodium (Masson 1951, Page 1955). After renin administration a further rise in 
blood pressure, proteinuria, severe edema and sometimes convulsions 
developed. Demonstrated lesions consisted of diffuse small hemorrhages and 
thrombi in several organs; in the kidneys swelling of endothelial cells was 
observed and tubular casts were formed (Masson 1952). A rise in blood 
pressure following high sodium intake and DOCA has also been described in 
uni-nephrectomized pregnant rats (Douglas 1971). 
Marked proteinuria and considerable weight gain was observed in 4 out of 20 
pregnant rats; 2 animals developed convulsions. Hemorrhagic lesions were seen 
in lungs, adrenals and placentas. The livers showed focal necrosis, and renal 
glomeruli were often occluded by endothelial swelling and fibrilar or 
granular deposits. The kidneys were most severely affected in animals who 
were treated during the whole pregnancy. Compared with a control group of 
pregnant rats an increased fetal death rate was observed in the DOCA-NaCl 
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treated animals (Douglas 1971). Vascular sensitivity to exogenous AII 
appeared to be increased in DOCA-NaCl treated pregnant rats (Douglas 1984). 
On the other hand, the physiologic fall in blood pressure near term which 
occurs in normotensive as well as in spontaneously hypertensive pregnant rats 
(Terragno 1983, Lorenz 1984), was also observed in DOCA-NaCl treated pregnant 
rats (Parks 1978). Such a fall in blood pressure was not found when the rats 
were treated with indomethacin, suggesting an intermediary role of the 
prostaglandin system (Parks 1978). Indeed, in pregnant rats near term there 
is a rise in the vascular production of prostacyclin in vitro and in the 
plasma concentration of prostacyclin metabolites (Williams 1978, Wilson 1982, 
Terragno 1983). In contrast to what usually occurs in the preeclamptic 
patient, the DOCA-NaCl treated rat still shows a fall in blood pressure near 
term, perhaps because prostacyclin production has remained within physiologic 
limits. It may be concluded that the rise in blood pressure and the 
development of organ lesions induced by DOCA in pregnant as well as in 
nonpregnant rats is probably due to unphysiologic doses of DOCA (and renin). 
Although the DOCA-NaCl-renin model may be used for the study of hypertension 
in pregnancy, it has produced no evidence of involvement of DOCA in the 
pathogenesis of pregnancy-induced hypertension. 
NUTRITIONAL FACTORS 
Despite a good number of investigations there is still no evidence that 
nutritional factors are involved in the etiology and pathophysiology of PIH 
(Chesley 1978, MacGillivray 1983). However, some nutritional factors may 
interfere with the regulation of blood pressure, in particular because of 
their possible influence on the production of prostanoids. 
In 5 late-pregnant sheep a rise in mean arterial blood pressure and 
peripheral resistance, and a fall in uterine artery blood flow and glomerular 
filtration rate were observed following 72 hours of fasting. In addition, the 
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development of proteinuria and kidney lesions .characteristic of human PIH was 
observed. The same treatment produced no changes in nonpregnant ewes 
(Thatcher 1986). In a subsequent report results were presented of platelet 
counts and function, and of prostacyclin and thromboxane measurements in this 
animal model (Keith 1987). In the hypertensive animals platelet counts 
were decreased, and plasma 6-keto-PGF1a and TXB 2 levels showed a slight 
but not significant decrease as compared to the situation before starvation. 
Treatment with a selective thromboxane synthetase inhibitor restored mean 
arterial blood pressure and platelet counts and function to values comparable 
to those before starvation. After inhibition of thromboxane synthesis TXB2 
levels were not significantly different from values before and during 
starvation; levels of 6-keto-PGF1a were even higher than before 
starvation, perhaps due to the shunting of substrate from thromboxane to 
prostacyclin synthetase. The possible pathophysiologic mechanism in this 
animal model may be the development of an imbalance of prostacyclin-
thromboxane action, perhaps caused by reduced prostacyclin action in 
ketonemic animals (Keith 1987). 
The PGI
2
/TXA 2 balance may also be influenced by vitamin E. Already in the 
early sixties vitamin E deficiency was reported to lead to trophoblast 
degeneration, placental infarction, and DIC in pregnant rats (Stamler 1959, 
McKay 1963, 1967). In vitamin E supplemented nonpregnant rats a higher aortic 
production of PGI 2 in vitro and a lower TXB 2 production by platelets was 
found, as compared with that in vitamin E deficient rats (Karpen 1981, 
Valentovic 1982). This effect may be due to protection of platelets and 
vessel wall from accumulating lipid peroxydes by the free radical scavenging 
effect of vitamin E (Okuma 1980, Srivastava 1986). 
In pregnant rats a vitamin E deficient diet reduced PGI 2 production in 
mesometrial triangles and aorta, and lipid peroxyde plasma levels increased. 
Effects were more marked when the diet was more oxidized. Fetal weight was 
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lower in the vitamin E deficient group (Spitz 1983, 1985). In these 
experiments no data on blood pressure or proteinuria were reported. Douglas 
(1966), however, could not find a rise in blood pressure or proteinuria in 
vitamin E deficient pregnant or nonpregnant rats. In spontaneously 
hypertensive nonpregnant rats a diet deficient in essential fatty acids 
resulted in a rise of systolic blood pressure (Church 1977). Supplementation 
of linoleic acid, the precursor of the prostaglandin-1 and -2 series, 
prevented the development of hypertension in nonpregnant rats fed on a 1.5% 
salt solution (Triebe 1976, Ten Hoar 1978); this effect was attenuated by a 
high dose of aspirin (Ten Hoar 1978). In nonpregnant rats, made hypertensive 
by renal artery constriction and contralateral nephrectomy, only a small and 
non -significant fall in systolic blood pressure was observed with a linoleic 
acid enriched diet as compared with the effects of a standard diet in a 
control group (Mahoney 1983). The aortic PGI 2 and renal PGI2 and PGE2 
synthesis in the linoleic acid supplemented group did not differ from that 
in the standard diet group (Mahoney 1983). 
In man Eicosapentanoic acid (EPA) as well as its precursor linolenic acid may 
have an influence on blood pressure and platelet aggregation because of 
conversion into PGI
3
, the active counterpart of PGI
2
, and synthesis of TXA
3
, 
the much less vasoactive and thrombogenic counterpart of TXA 2 (Lorenz 1983). 
In rats, however, there is some evidence that the effects of EPA and 
linolenic acid caused by increased synthesis of the prostaglandin-3 series 
are overwhelmed by their influence on the production of PGI 2 and TXA 2 , 
because of inhibition of cyclo-oxygenase (Scherhag 1982). A decreased PGI 2 
production with an EPA and/or linolenic enriched diet has been observed in 
nonpregnant rats (Hornstra 1979, 1981, Scherhag 1982, Mahoney 1983). In 
contrast, Hamazaki (1982) reported an increased production of PGI 2 from 
aortic segments in vitro in male Wistar rats with an EPA enriched diet as 
compared to control rats. The release of platelet TXA2 has been reported to 
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be slightly (Scherhag 1982) or significantly (Hornstra 1979, 1981) decreased 
in nonpregnant rats fed an EPA or linolenic acid enriched diet, and PGI
3 
production was found to be rather small or even absent in these nonpregnant 
rats (Hornstra 1981, Hamazaki 1982). 
The effects of EPA and linolenic acid on systolic blood pressure in 
nonpregnant rats appear to be variable; it was found to be slightly but 
not significantly decreased in hypertensive rats after renal artery 
constriction and contralateral nephrectomy (Mahoney 1983) and increased in 
normal nonpregnant rats (Scherhag 1982). 
The effects of dietary supplementation of essential fatty acids on 
prostaglandin synthesis and blood pressure in pregnancy are not known, since 
all the experiments mentioned earlier were performed in nonpregnant animals. 
So far there are no data that essential fatty acids are involved in the 
pathophysiology of PIH, but it remains an interesting field for further 
investigations. 
VASOACTIVE SUBSTANCES 
Blood pressure in pregnant animals appears to be the same or lower as 
compared to that in nonpregnant animals (Berssenbrugge 1980, Danker 1983, 
Paller 1984, Venuto 1984, Losconzy 1986-87, Weiner 1987), which is possibly 
caused by an increased synthesis of vasodilatory prostaglandins. Inhibition 
of prostaglandin synthesis by meclofenamate did not change mean arterial 
blood pressure in either pregnant or nonpregnant rabbits or rats (Danker 
1983, Paller 1984, Venuto 1984), but in pregnant sheep an increase in mean 
arterial blood pressure was found following indomethacine (Rankin 1979a). 
Following captopril, an inhibitor of angiotensin I converting enzyme, mean 
arterial blood pressure was slightly decreased in pregnant rats and 
significantly so in pregnant rabbits, but it remained unchanged in 
nonpregnant rats and rabbits (Danker 1983, Paller 1984). Blockade of 
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I. 
I 
a-receptors resulted in a slight decrease of blood pressure in nonpregnant 
and a more pronounced decrease of blood pressure in pregnant rabbits 
(Berssenbrugge 1980, Venuto 1984). 
In analogy to human pregnancy a reduced vascular responsiveness to exogenous 
vasoactive substances like All, norepinephrine and vasopressin has been 
observed in rats, rabbits and guinea pigs during pregnancy (Berssenbrugge 
1980, Danker 1983, Paller 1984, Venuto 1984, Weiner 1987). The reduced 
vascular response in pregnancy to vasoactive substances seems to be caused by 
circulating vasodilatory agents, since this phenomenon could not be shown in 
vitro in studies with isolated arterial strips from pregnant rabbits (Moisey 
1983). The blunted response to exogenous All in pregnancy can also not be 
attributed to reduced All receptor affinity or receptor number, or increased 
occupancy of vascular All receptors by high circulating levels of endogenous 
All, as shown in pregnant rats (Paller 1984). The reduced vascular pressor 
response in pregnancy is more likely to be produced by the increased 
synthesis of vasodilatory prostaglandins like PGl 2 and PGE2 • Inhibition of 
prostaglandin synthesis by cycle-oxygenase inhibitors has been shown to 
increase the vascular response to exogenous Ali, noradrenaline and 
vasopressin in pregnant animals, in many of which the pressor response became 
equal to that in nonpregnant animals. In nonpregnant animals inhibition of 
prostaglandin synthesis had little or no influence on the pressor response of 
exogenous vasoactive substances (Danker 1983, Paller 1984, Venuto 1984, 
Weiner 1987). 
The reduced blood pressure is possibly, and the decreased pressor response 
to exogenous vasoactive substances in pregnancy is probably the result of an 
increased production of vasodilatory prostaglandins like PGE 2 and PGI 2 , which 
has been demonstrated in rats and rabbits (Venuto 1982, 1984, Danker 1983, 
Terragno 1983). Endogenous All and norepinephrine both play a role in the 
maintenance of blood pressure in pregnancy. The concept that elevated levels 
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of All and . norepinephrine in pregnancy are necessary to counteract the 
vasodilatory activity of prostaglandin (Venuto 1984) is supported by the 
decreased plasma renin activity, which was observed after inhibition of 
prostaglandin production in pregnant rabbits (Danker 1983). 
Not only the systemic circulatory effects of prostaglandins and vasoactive 
substances are important, but in particular also their effects on the 
uteroplacental circulation. Inhibition of prostaglandin synthesis by 
indomethacine in pregnant sheep resulted in a fall in placental and 
nonplacental uterine blood flow (Rankin 1979a). In pregnant rabbits a 
significant fall in placental blood flow was observed following 
indomethacine, but nonplacental uterine blood flow was unchanged (Katz 1981). 
Administration of the vasodilator prostaglandin PGI 2 increased uterine blood 
flow in nonpregnant sheep (Resnik 1980, Clark 1981). In pregnant sheep 
prostacyclin has been reported to increase uterine blood flow (Clark 1982). 
However, Rankin (1979b) found an increase in nonplacental uterine blood flow 
only, whereas placental flow appeared to be significantly decreased. These 
changes were associated with a marked drop in blood pressure, which may in 
part explain the fall in uterine placental blood flow. The decrease in 
uterine placental blood flow following PGI 2 could also be a result of 
enhanced responsiveness to All in uterine placental vessels, as observed in 
pregnant ewes receiving All and PGI 2 infusions. In contrast, responsiveness 
in· renal and uterine nonplacental vessel·s to exogenous All appeared to be 
reduced during PGI 2 infusion (Parisi 1985). Vasodilator PGE 2 in pregnant 
sheep was shown somewhat unexpectedly to reduce total uterine and placental 
uterine blood flows; this effect may be due to myometrial contraction (Rankin 
1976; Clark 1982) because PGE 2 administered to the fetus caused an increase 
in placental uterine blood flow after being transferred across the placenta 
(Rankin 1976). 
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All the observations above have been made in normotensive pregnant animals, 
which makes it difficult to extrapolate them to human pregnancy complicated 
by PIH. However, just like in .human pregnancy, a decrease in vasodilator 
prostaglandin action in animal pregnancy may have important effects on 
vasoconstriction and blood flow, although the effects of vasodilator 
prostaglandins on the uteroplacental circulation are still unclear. 
IMMUNE SYSTEM 
Publications concerning animal models to induce PIH on an immunologic basis 
are limited to descriptions of experiments with sensitization to placental 
extracts or administration of antiplacenta sera. In nonpregnant rats 
sensitization against homologous placental extracts has been reported to 
result in an increase in blood pressure, proteinuria and glomerulonephritis. 
Pregnancy occurring some months later ended in abortion, intrauterine death 
or poor fetal growth, but blood pressure was not recorded in these 
experiments (Okuda 1966). 
Administration of rabbit anti-rat placenta serum to nonpregnant and pregnant 
rats was found to cause chronic glomerulonephritis and an increased abortion 
rate (Seegal 1946). After administration of rabbit anti-rat placenta serum 
hypertension developed in pregnant, but not in nonpregnant rats, and kidney 
lesions were found in pregnant and nonpregnant rats (Langford 1967). The 
renal lesions caused by rabbit anti-rat placenta serum may be due to 
antigenic cross reactivity shared by placental and renal antigen, This could 
explain the increased blood pressure and proteinuria, but Langford (1967) 
observed hypertension in pregnant rats only. As th~ rabbit anti-rat placenta 
serum also effects trophoblast cells, in particular those that are in direct 
contact with the mother (Franke 1971), it is tempting to speculate that 
placental damage was involved in the development of the hypertension in these 
animals. 
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If sensitization of the maternal immune system against placental and kidney 
antigens were an important mechanism in the pathogenesis of PIH, one would 
expect an increase in the frequency of occurrence of PIH in multiparous 
women. This is not the case, and a simple immunologic model as mentioned 
above'cannot explain the many features of the disease in man. 
Like in man an interplay between rejection and adaptation of the fetus by the 
maternal immune system can be expected in animals. An increase in litter 
size, and in placental and fetal weight was found after crossbreeding of 
inbred rat and mouse strains (Billington 1964, Beer 1975, Beer et al 1975). 
This effect was diminished by removal of paraaortic lymph nodes before 
mating, which suggests that not only heterosis, but also maternal immune 
reactions play a part (Beer 1975, Beer et al 1975). 
Thus, like in man, histoincompatibility seems to favor pregnancy. This 
protective effect is perhaps the result of an enhanced maternal antibody 
response and a weakened or eliminated cell-mediated immune response to the 
fetal allograft due to exposition to incompatible class I MHC trophoblast 
antigens, in the absence of class II antigens (Wegmann 1981, Head 1982). 
Hyporesponsiveness to paternal alloantigens is increased with increasing 
parity (Head 1982), suggesting an increase in formation of blocking 
arttibodies. The heterogeneic advantage of crossbreeding was not found in all 
inbred strain combinations and in some crossbreedings of inbred mouse and rat 
strains incompatibility of non-MHC antigens appeared to have a negative 
effect on the outcome of pregnancy (Palm 1974, Milgram 1977, Croy 1982, 
Dawson 1982). In these experiments the relationship between fetomaternal 
immunologic interaction and the problem of PIH was not investigated. 
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IV CONCLUSIONS 
Spontaneous "PIH-like'' syndromes are rare in pregnant animals and in most 
cases they have been insufficiently documented. Major signs like hypertension 
and proteinuria were usually not found or reported. Pre-existent diseases 
such as hypertension or renal disorders were not ruled out. Many of the signs 
of spontaneous "PIH" in animals are of metabolic origin, and c~n also be 
observed in nonpregnant animals. It remains doubtful whether spontaneous PIH 
really exists in animal pregnancy. 
Several factors seem to be involved in the pathogenesis and pathophysiology 
of PIH in man, some of which have been studied in animal pregnancy. 
Prostaglandins are important in the regulation of blood pressure in 
pregnancy, but their effects on uterine, placental and fetal blood flow are 
not fully understood. In PIH in man the PGI 2/TXA 2 balance appears to be an 
important factor in the development of the disease. The role of nutritional 
factors in human PIH is most likely limited. However, some nutritional 
factors may influence the prostaglandin metabolism and thus interfere with 
the regulation of blood pressure. For that reason the demonstrated influence 
of essential fatty acids and vitamin Eon the prostaglandin metabolism is 
interesting, and may have a bearing on the pathophysiology of PIH and perhaps 
also on the treatment of the disease. Further investigations of these dietary 
factors could be useful. An interesting observation has been made in 
ketonemic pregnant sheep following starvation. These animals developed 
hypertension, proteinuria, decreased placental blood flow, and changes in 
platelets, prostacyclin and thromboxane production. Inhibition of thromboxane 
synthetase in these animals appeared to be beneficial. 
The vasoregulatory mechanisms of the renin-angiotensin system seem to play a 
secondary part in the pathogenesis and pathophysiology of PIH. Although 
progesterone may influence vascular refractoriness to various vasoactive 
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metabolites, and DOCA has been shown to increase blood pressure in animals, a 
role of steroid hormones remains questionable. 
tn various animals with experimentally induced placental ischemia 
hypertension, proteinuria, coagulation disorders and histological lesions 
were observed. However, even in severe human preeclampsia fetal growth 
retardation is not always present, and in animals with induced placental 
ischemia the production of vasodilatory prostaglandins appeared to be 
increased, perhaps as a compensatory mechanism. It cannot be concluded that 
placental insufficiency is a primary phenomenon in the pathogenesis and 
pathophysiology of PIH. 
The role of immunologic factors in PIH is unclear. In man as well as in 
animals MHC-incompatibility appears to be favorable with regard to the 
outcome of pregnancy. In contrast, non-MHC incompatibility may have a 
negative effect on the progeny. Further immunologic experiments in animals 
are needed to support or refute the concept that PIH is a disease of 
immunologic maladaptation of the mother to the fetal allograft. The 
relationship between immunologic dysfunctioning and the production of 
vasoactive substances, especially prostacyclin and thromboxane, needs further 
investigation. 
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ABSTRACT 
Because of the possible influence of fetomaternal incompatibility on the 
occurrence of pregnancy-induced hypertensive disease and the outcome of 
pregnancy a comparative study was performed in 25 Wistar female rats bred 
with Wistar males, 33 Wistar females bred with Brown Norway males and 12 
Wistar females bred with Brown Norway males treated with the antiplatelet 
drug ticlopidine. 
Thirteen nonpregnant Wistar females were used as controls. Blood pressure 
near term was reduced in all pregnant animals as compared with nonpregnant 
controls, but the decrease in bloodpressure was less Rronounced in crossbred 
pregnancies. Maternal weight and uterine arterial 6·keto-PGF1a production 
were lower in crossbred than in non-crossbred animals and proteinuria was 
found to be increased. In the crossbred ticlopidine group, 6-keto-PGF1a 
production was in the same range as that in nonpregnant animals and blood 
pressure and proteinuria were comparable with those in the non/crossbred 
group. It is concluded that fetomaternal incompatibility in this model 
increases the susceptibility of developing a pregnancy-induced hypertensive 
disorder. 
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INTRODUCTION 
The etiology of pregnancy-induced hypertension (PIH) in man remains unknown. 
Although symptoms resembling those of PIH have been reported to occur 1n 
animal pregnancies, it is unlikely that the disease develops spontaneously 
in animals (Douglas 1971). Various experimental approache~ have been used to 
induce PIH in pregnant animals, mostly based on the induction of placental 
ischemia. However, placental ischemia is not always present in human PIH, and 
there is evidence that immunologic factors may be involved in the 
development of PIH (Beer 1978, Redman 1981). HLA-dissimilarity between mother 
and fetus seems to protect against the development of PIH (Jenkins 1978, 
Redman 1978). In experimental animals fetomaternal compatibility has been 
shown to result in reduction in litter size, fetal and placental weight, 
possibly due to immunologic factors (Billington 1964, Beer 1975). However the 
results of these animal experiments do not elucidate the pathogenesis of PIH 
since blood pressure was not measured. 
To investigate the effects of immunologic factors on circulatory adaptation, 
course and outcome of pregnancy we developed a heterogeneous rat model, by 
crossbreeding female Wistar rats with Brown Norway males. Maternal variables 
such as blood pressure, proteinuria and weight were determined, and litter 
size and fetal weight were assessed. Because there is increasing evidence 
that the balance of vasodilator substances such as prostacyclin (PGI
2 
) and 
vasoconstrictors such as thromboxane A2 (TXA 2 ) is involved in the 
pathogenesis of PIH (Wallenburg 1981, Ylikorkala 1985), the in vitro 
production of PGI 2 by uterine arteries was also studied. 
MATERIALS AND METHODS 
Seventy-three virgin Wistar rats were mated at 8-10 weeks of age and 
conception was confirmed by inspection of the vaginal plug. After mating 
animals were kept in standard cages, 6 animals per cage. Food an~ water were 
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supplied ad libitum. Forty-eight Wistar females were mated with Brown Norway 
males, and 25 Wistar females were mated with Wistar males. Thirteen 
nonpregnant virgin Wistar rats, aged 8-10 weeks, served as controls. 
In order to study the influence of prostaglandins on the outcome of pregnancy 
14 of the crossbred animals received the anti-platelet drug ticlopidine, 
administered in a dose of 25 mg on day 6, 8, 11, 13, 15 and 18 of pregnancy 
by means of a stomach canula. With this dose, effective inhibition of 
platelet aggregation in rats is achieved for several days (Ashida 1978). 
Systolic blood pressure was measured on day 19 of pregnancy in conscious rats 
using a tail cuff (Palbol 1979). Measurements were repeated with intervals of 
2 minutes until 3 stable values were obtained. On day 20 urine was collected 
after spontaneous voiding and the degree of proteinuria was assessed using 
Albym-test reagent sticks (Boehringer Ingelheim). Anesthesia was then induced 
with pentobarbitone sodium, the animal was weighed, the abdomen was opened, 
and the uterine arteries were removed and stored in 0.1 M Tris buffer, pH 7.4 
at 4° C. The whole uterus was removed and the animal was killed with an 
overdose of pentobarbitone sodium. The numbers of living and dead fetuses 
were recorded, and all fetuses were weighed. Nonpregnant rats were treated 
in the same fashion and sacrificed at 8-10 weeks of age. 
Equal parts of uterine arteries were used for measurement of 6-keto-PGF1a 
production. Each part was cut into small pieces (Me Ilwain tissue chopper) 
at 4o C. The pieces were incubated in siliconized aggregation tubes (Paytoon) 
at 37° C under stirring (900 rpm) in 0.5 ml of Tris buffer (50 mM; pH 6.8) 
for 1 hour, and 20 ~1 of the supernatant was taken for radioimmunoassay of 
6-keto-PGF1a using commercial RIA-kits (NEN, Boston, USA). The sensitivity 
of the assay is within a range of 10-1000 pg. Amounts were found in ranges of 
30-70% B/Bo. Cross reactivity of &-keto-PGF2 and PGE 2 was $ 8%, and of 
other eicosanoids $ 0.1 %. Data were expressed as nanograms per sample of 
uterine artery. 
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TABLE 1 Systolic Blood Pressures and Production of 6-keto-PGF1a 
(mean ± SO) by Uterine Arterial Tissue in NonPregnant Rats, and 
in Crossbred and Non-Crossbred Pregnant Rats. 
Wistar W X W W x Br.N. W x Br.N. 
(ticloQidine) 
nonQregnant non-crossbred crossbred 
Experimental 
animals (n = 13) (n = 25) (n = 33) 
Systolic blood 108 ± 5 89 ± 5 99 ± 7 
pressure (mmHg) A AB 
6-KetoPGF1a 1.93 ± 0.90 3.04 ± 1.17 2.42 ± 1.24 
(ng/sample) A c 
A. p < 0.005 compared with Wistar nonpregnant 
B. p < 0.005 compared with WxW and WxBrN (ticlopidine) 
C. p < 0. 05 compared with WxW 
D. p < 0.005 compared with WxW 
E. p < 0.025 compared with WxBrN 
TABLE 2 Maternal Weight and Fetal Outcome (means± S.D.) 
Wistar W X W 
nonQregnant 
Animals (n=13) (n=25) 
Maternal weight 177. 94±21. 79 338.13±41. 26 
(gram) A 
Littersize 11. 20± 2. 62 
Fetal weight 
(gram) 
3.47± 0.65 
Fetal death 21 
E 
A p < 0.005 compared with W nonpregnant 
B p < 0. 005 compared with WxW 
C p < 0.005 compared with WxW 
D p < 0.005 compared with WxBrN(ticlopidine) 
W x Br.N 
(n=33) 
267.80±38.28 
AB 
8.73± 2.91 
c 
3.63± 0.32 
0 
7 
E p < 0.005 compared with WxBrN and with WxBrN(ticlopidine) 
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(n = 11) 
89 ± 8 
A 
1.65 ± 0.43 
DE 
W x Br.N 
(ticloQidine) 
(n=ll) 
262. 32± 41.85 
AB 
10.27± 3.72 
3.14± 0.56 
0 
Averages and standard deviations of fetal and maternal weight, systolic blood 
pressure and 6-keto-PGFla production were calculated. Differences were 
statistically analyzed using Wilcoxon's test, and p < 0.05 was considered to 
represent significance. 
RESULTS 
In the crossbred group 4 animals, 3 of which were receiving ticlopidine, 
appeared to be not pregnant and for this reason they were removed from the 
study. Systolic blood pressure appeared to be significantly lower in all 
pregnant animals as compared with that in nonpregnant animals (Table 1). The 
lower systolic blood pressure was more pronounced in the non-crossbred and in 
the ticlopidine crossbred animals: the mean values of these two groups were 
significantly different from those in the untreated crossbred group. 
In all pregnant animals 6-keto-PGF1a production by uterine arterial tissue 
was significantly elevated as compared with that in nonpregnant controls, 
but 6-keto-PGFla production was lower in crossbred than in non-crossbred 
animals. Values in ticlopidine treated crossbred rats were even lower than 
those in nonpregnant animals (Table 1). 
The highest maternal weight near term was found in the non-crossbred group, 
which could only in part be attributed to the total weight of the fetuses. In 
the untreated crossbred group litter size was significantly lower than that 
in the non-crossbred group. The highest mean fetal weight was observed in the 
untreated crossbred group. Little difference in fetal weight between groups 
was found and although mean fetal weight was highest in the untreated 
crossbred group the mean fetal weight in the non-crossbred group was higher 
when corrected for litter size (fig. 1). 
Fetal death occurred significantly more often in the Wistar x Wistar group 
than in the other groups (table 2). In almost all rats at least a trace of 
proteinuria could be found. In the crossbred group (without ticlopidine) 
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FIG. 1: Correlation between relative fetal weight (%) at day 20 of gestation 
and relative litter size (%). Fetal weight of 5.20 g and litter size 
of n=16 were taken as 100%. 
~~~:-~._ = Wistar x Wistar, r=0.86 C:::::: 90% confidence 1 imits) 
~ = Wistar x Br. Norway, r=0.65 c==== 90% confidence 1 imits) 
proteinuria ~ 0.3 g/1 occurred more frequently (58%) than in the non-
crossbred group (24%) and in the ticlopidine crossbred group (22%). 
In the cro~sbred Wistar - Brown Norway group (without ticlopidine) litter 
size was significantly smaller than in the other groups. When the Wistar x 
Brown Norway group (without ticlopidine) was divided into a group with litter 
size :;; 8 and a group with 1 i tter size 10-12, no differences between groups 
could be demonstrated (table 3), except for the number of dead fetuses which 
was 1 in the group with litter size 10-12, and 6 in the group with litter 
size :;; 8. 
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TABLE 3 Wistar x Brown Norway, different litter size 
Litter size group 
Animals 
Syst. blood pressure (mm Hg)* 
6-keto-PGF1 a (ng/sample)* 
Maternal weight (gram)* 
Litter size* 
Fetal weight (gram)* 
Fetal death 
* means ± S.D 
DISCUSSION 
:;; 8 
(n=12) 
102 ± 8 
2.63± 1.67 
245.60±25.54 
5.50± 2.20 
3.74± 0.41 
6 
10-12 
(n=17) 
99 ± 8 
2.42± 0.98 
283. 61±36. 72 
10.71± 0.69 
3.63± 0.25 
1 
Prostacyclin (PGI 2 ), an important endogenous vasodilator with strong platelet 
anti-aggregation potency, and thromboxane (TXA
2
), with opposite effects, are 
supposed to be important pathogenetic factors in human PIH. A shift of the 
physiologic balance between PGI 2/TXA 2 to the dominance of the effects of TXA 2 
could explain the vasoconstriction and enhancement of platelet aggregation 
that occurs in PIH (Ylikorkala 1985). In rat pregnancies near term increased 
levels of 6-keto-PGF1a have been found in uterine, placental and arterial 
tissue, amniotic fluid and uterine venous plasma (Zamecnik 1980, Wilson 
1982). We also found elevated in vitro production of 6-keto-PGF1a and a 
significantly lower blood pressure in pregnant animals when compared with 
nonpregnant animals. However, the blood pressure appeared to be higher and 6-
keto-PGF1a production lower in the crossbred group when compared to that in 
the Wistar x Wistar group. Although the capacity to produce 6-keto-PGF1a is 
at least influenced in part by the fetoplacental unit (Wilson 1983) we could 
not find differences in 6-keto-PGF1a production between crossbred animals 
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with small ( ~ 8) and normal sized (10-12) litters. Proteinuria tended to be 
elevated in crossbred untreated animals. 
The reduced 6-keto-PGF1a production by uterine arteries in vitro and the 
higher blood pressure-resemble the symptoms of PIH in man. Fetal growth 
retardation, a common finding in PIH in man 1 was not observed in our rat 
model, and in fact the number of fetal deaths was larger in the Wistar x 
Wistar group. However, it cannot be excluded that the smaller litter size in 
the Wistar x Brown Norway group may have been caused by early fetal death 
followed by complete absorption. 
In order to study the influence of prostaglandins on the results obtained in 
our model some of the crossbred rats were treated with ticlopidine. 
Ticlopidine is a powerful anti-platelet agent with a permanent effect on the 
platelet membrane. Ticlopidine does not inhibit platelet cyclooxygenase and 
has no effect on thromboxane synthetase, but it enhances the inhibitory 
effect of prostacyclin on platelet aggregation (Panak 1983). In the crossbred 
rats treated with ticlopidine we found a lower blood pressure and a reduced 
production of 6-keto-PGF1a as compared with that in untreated crossbred 
animals. A decrease of 6-keto-PGF1a production would be expected to lead to 
hypertension, unless TXA2 production is also reduced with a shift of the PGI2 
/TXA 2 balance towards PGI 2 • Platelet aggregation is a common feature in PIH 
in man, in particular when combined with fetal growth retardation, and could 
be a major source of TXA 2 production. In most cases thrombocytopenia in PIH 
is mediated by thrombin independent mechanisms (Gibson 1982, Wallenburg 
1987). Ticlopidine has no direct effect on TXA
2 
production, but during 
ticlopidine treatment in man decreased levels of TXB
2 
(the major stable 
metabolite of TXA 2 were found following in vitro supplementation of 
arachidonic acid in patients with enhanced platelet aggregation. Platelet 
TXB 2 production was not influenced by thrombin stimulation (Gensini 1983). In 
our model no TXB 2 measurement or platel-et life-span studies were performed, 
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but the reduced blood pressure in combination w_ith a decreased , 6-keto-PGFla 
production suggests a further suppression of TXA 2 due to inhibition of 
platelet aggregation by ticlopidine. 
In our experiments fetomaterna 1 i ncompati bi 1 i ty had no fa vorab 1 e effect on 
pregnancy outcome in contrast with the improved pregnancy outcome reported in 
case of increased major histocompatibility complex (MHC) antigen 
incompatibility by crossbreeding two inbred strains (Billington 1964, Beer 
1978). We did not use 2 inbred strains, but a random bred Wistar strain and 
an inbred Brown Norway strain. MHC incompatibility in the random bred Wistar 
strain can be expected to be strong enough to warrant normal pregnancy 
outcome. Incompatibility of non-MHC-antigens may have a negative effect on 
pregnancy outcome (Palm 1974, Dawson 1982), which may explain the unfavorable 
outcome in our model. Further investigation in this animal model is required 
to provide information on the relationship between the immune system and PIH. 
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ABSTRACT 
To investigate the role of immunity on the course of pregnancy, with special 
emphasis on changes found in human pregnancy-induced hypertension, 
pregnancies of 44 crossbred female Wistar rats x Brown Norway males were 
compared with those of 25 Wistar x Wistar couples, with particular reference 
to 6-keto-PGFla production by uterine arteries, and the histologic features 
of placenta and liver. All female rats were of the same age and nulliparous. 
Eleven crossbred animals received the platelet aggregation inhibiting agent 
ticlopidine during gestation. After crossbreeding, elevated blood pressures, 
increased levels of proteinuria, and a reduced uterine arterial 6-keto-PGFla 
production were found, in analogy with finqings in pregnancy-induced 
hypertension (PIH) in man. These changes were in part prevented by treatment 
with ticlopidine. Increased labyrinthine giant cells, trophoblast 
proliferations, and extramedullary hematopoiesis in fetal liver were found 
after crossbreeding, suggestive of placental and fetal ischemia. These 
changes were only partly prevented in placentas after ticlopidine medication. 
It is concluded that fetomaternal incompatibility in this model may lead to a 
disturbance of the maternal uteroplacental adaptation and fetal and placental 
hypoxemia. 
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INTRODUCTION 
The immune system is supposed to play a role in the pathogenesis of 
Pregnancy-Induced Hypertension (PIH) (Beer 1978, Redman 1981). In animal 
experiments fetomaternal incompatibility seems to be advantageous for the 
outcome of pregnancy (Palm 1974, Beer 1975), although exceptions exist (Palm 
1974, Dawson 1982). However, none of the reported experiments allows 
conclusions with regard to the pathogenesis or pathophysiology of PIH. 
In an attempt to investigate the effects of incompatibility on the course of 
pregnancy, in particular with regard to the development of PIH, we designed 
an immunologic heterogeneity model by crossbreeding female Wistar rats with 
Brown Norway males. In this model maternal expressions of PIH, such as an 
elevated blood pressure, increased levels of proteinuria, and decreased in 
vitro 6-keto-PGF1a production by uterine arteries, were found, which closely 
resembles PIH in man. These signs could in part be prevented by ticlopidine 
treatment during pregnancy (Hutten, accepted for publication). 
Because PIH is often accompanied by an impaired placental circulation, 
expression of fetoplacental ischemia was investigated in the animal model. 
Proliferation of trophoblast cells and fetal extramedullary hematopoiesis 
(EMH) were chosen as indicators of placental and fetal ischemia, 
respectively. In the labyrinthine placenta of the rat syncytial trophoblast 
cells and labyrinthine giant (trophoblast) cells can be distinguished. 
Quantification of placental labyrinthine trophoblast cells and liver 
extramedullary hematopoietic cells was performed in order to study possible 
signs of increased ischemia in the crossbred group. 
MATERIALS AND METHODS 
Seventy-three nulliparous Wistar rats were mated at 8-10 weeks of age and 
conception was confirmed by inspection of the vaginal plug. Animals were kept 
in standard cages, 6 animals per cage. Food and water were supplied 
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ad libitum. Forty-eight Wistar females were mated with Brown Norway males, 25 
Wistar females were bred with Wistar males. Thirteen nonpregnant nulliparous 
female Wistar rats aged 8-10 weeks served as controls. 
Because platelet aggregation is common in PIH in man and may influence the 
prostacyclin-thromboxane balance which may interfere with the disease 
(Wallenburg 1987), platelet aggregation was inhibited in 14 crossbred rats by 
means of treatment with the antiplatelet agent ticlopidine in a dose of 25 mg 
on day 6, 8, 11, 13, 15 and 18 of pregnancy (Hutten, accepted for 
publication). 
Animals were sacrificed on day 20 of pregnancy. Fetuses and placentas were 
fixed in 70% ethanol for at least 24 hours. Of each pregnancy one fetus and 
placenta were embedded in paraplast following routine histologic procedures. 
Placentas were cut transversally through the center and fetuses sagitally 
through the midline and vertebral column. Sections ( 4 ~ m) were stained with 
hematoxylin without counterstain (see figures 1 and 2). The sections were 
examined, using established methods of morphometric quantitation (Aherne 
1982). The adequate sample size for counting placental trophoblast and giant 
cells and fetal liver EMH cells was determined using the minimal sample size 
assessment through the method of running means. A sample size was chosen that 
resulted in average values and standard deviations within 2,5% of final means 
and standard deviations. Reproducibility studies revealed intra- and inter-
observer variation coefficients less than 3% for the cells investigated. 
Area selection for extraction of parameters was performed as follows: In the 
placenta the center was found using an eyepiece grid in the microscope (Nikon 
UWF and 2 x Plan-apochromat objective) and a line parallel to the placental 
base was chosen. This line was divided in four equal parts. Because perfusion 
of blood is lowest in the lateral parts of ~he placenta, studies on placental 
ischemia were performed in these parts. Eight photographs of adjoining areas 
from the lateral parts of this virtual line were taken per placenta using a 
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A 
FIG. 1. 
A 
FIG. 2. 
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B 
Placentas from Wistar x Wistar (A) and Wistar x Brown Norway 
~arrow at labyrinthine giant cell,,._arrow at trophoblastic 
(hematoxylin staining, original magnification: 200 x). 
B 
(B). 
cell 
Fetal livers from Wistar x Wistar (A) and Wistar x Brown Norway (B). 
~arrow at hepatocyte,,._ arrow at island of EMH (hematoxylin 
staining, original magnification: 400 x). 
20 x objective and 10 x photoocular. In the fetuses the center of the upper 
abdominal transversal diameter was measured. From there a line was drawn at a 
right angle through the diaphragm. From the transsection of this line and the 
subdiaphragmatic liver capsula, 2 frames per direction were taken, in ventral 
and dorsal directions, using a 40 x objective and a 10 x photoocular. Images 
were projected on a grated screen (80x100 em) divided into 10x10 em squares, 
using a standard projector. Cell populations were analyzed in a random 
sequence, without the investigator being aware of the clinical background of 
the animal; nuclei were identified as either trophoblastic, giant cell or 
' 
''other" in the placenta, and the subpopulations were counted per slide. The 
number of placental cells were expressed as number of nuclei per square mm of 
tissue. In the livers nuclei were identified as hepatocytic or non-
hepatocytic, assuming that the majority of the non-hepatocytic nuclei are 
related to EMH. 
For details of histology see figures 1 and 2. Results of cell counting were 
tabulated and means and standard deviations were calculated. Differen~es were 
statistically analyzed using Wilcoxon's test, and p < 0,05 was considered to 
represent significance. 
RESULTS 
One animal iri the crossbred group and three in the ticlopidine treated 
crossbred group were not pregnant. Numbers of labyrinthine trophoblast and 
giant cells were found to be significantly elevated in the crossbred group, 
as compared to those in the non-crossbred group (Table 1). Ticlopidine 
treatment had no demonstrable effect on the number of labyrinthine 
trophoblast cells. However, ticlopidine significantly reduced the number 
of labyrinthine giant cells (p < 0.001), although it remained higher in the 
crossbred group than in the non-crossbred animals. Liver cells as analyzed by 
hepatocyte nuclei counting did not differ between the three groups. 
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The amount of EMH, as analyzed by absolute numbers of non-hepatocytic nuclei, 
and the EMH/liver cell index were significantly increased in livers of 
crossbred fetuses. No significant difference was apparent between the group 
with and'that without ticlopidine treatment. 
TABLE. 1 Histologic Features (means ±S.D.) of Placenta and Fetal Liver 
in Experimental Animals and Controls. 
Animals 
Labyr.trophobl. 
cells nuclei 
(10 3 mm-2 ) 
Labyr.giant cells 
·nuclei(103 mm-2) 
EMH (nucl/slide) 
Hepatocytes 
(nuclei/slide) 
EMH/hepatocytes 
ratio 
WistarxWistar 
n = 25 
1.5 ±0.35 
0.31±0.06 
76.94±27.17 
47.62±10.60 
1. 64± o. 42 
A = p < O;Ol compared with WxW 
B = p < 0.001 compared with WxW 
C = p < 0~01. compared with WxBrN 
DISCUSSION 
WistarxBr.Norway 
n = 33 
2.3 ± 0.39 
A 
0.58± 0.07 
B 
101.12±30.85 
A 
50.57±11.20 
2.01± 0.63 
A 
WistarxBr.Norway 
ticlopidine 
n = 11 
2.1 ± 0.45 
A 
0. 44± 0. 06 
B,C 
107 .91±38.38 
A 
54. 55± 14.03 
2.14± 1.07 
A 
The chorioallantoic placenta in man as well as in rats is hemochorial. The 
human placenta is of the villou~ type, whereas the rat placenta contains more 
differentiated areas like the labyrinth, the basal zone and a layer of giant 
cells (Garbis-Berkvens, accepted for publication). Only the labyrinth 
88 
contains fetal vessels, which are surrounded by 3 layers of trophoblast 
cells: one layer of metabolically active labyrinthine giant cells and two 
layers of syncytial trophoblast cells. The blood flow in the rat placenta is 
regulated through a central vessel, and hypoxia may be expected to occur 
first in the lateral parts (Garbis-Berkvens, accepted for publication). 
The results of our study show that crossbreeding Wistar with Brown Norway 
rats stimulates the development of labyrinthine trophoblast and giant cells 
in placentas and EMA in fetal livers when compared with non-crossbred Wistar 
x Wistar rats. Ticlopidine treatment during pregnancy in the crossbred group 
tends to prevent the placental but not the fetal liver changes. 
In human 
knots is 
pregnancy cytotrophoblastic activity and formation of 
known to be stimulated by placental ischemia (Rushton 
syncytial 
1984). In 
analogy with the changes seen in human hypoxic placentas, proliferation of 
both types of trophoblastic cells in the rat placenta may also be caused by 
hypoxemia. 
In the fetus we have found increased extramedullary hematopoiesis in the 
liver after crossbreeding, a feature that is also observed in experimentally 
growth-retarded guinea pigs (Lafeber 1981). Increased fetal hematopoiesis due 
to chronic hypoxia can also be found in human fetal and neonatal pathology 
(Naeye 1977, D'Souza 1981). 
The signs of hypoxia found in placentas and fetal livers after crossbreeding 
are consistent with the earlier described increase in blood pressure which is 
regarded as a reaction to decreased placental perfusion, proteinuria and 
reduced in- vitro uterine artery 6-keto-PGF1a production in these animals 
(Hutten, accepted for publication). The picture closely resembles that of PIH 
as it develops in man. 
Because increased platelet consumption is a common featu·re in PIH in man and 
appears to be associated with a disturbed PGI 2 /TXA 2 balance (Wallenburg 
1987), platelet aggregation was inhibited in a group of crossbred animals by 
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means of ticlopidine treatment. Placental changes during ticlopidine 
treatment are suggestive of a slight but significant improvement in placental 
oxygenation. Such an effect was not observed in the fetal liver, and in fact 
after ticlopidine treatment fetal weight also appeared to be decreased 
(Hutten, accepted for publication). Perhaps the increased average litter size 
in rats receiving ticlopidine (10,27 vs 8,73) in combination with the slight 
improvement of the placental function may be responsible for the lower 
average fetal weight in this group. 
In the model described in this report fetomaternal incompatibility appeared 
to be unfavorable for the outcome of pregnancy. In man an increased incidence 
of spontaneous abortion (Komlos 1977, Thomas 1985) and PIH (Jenkins 1978, 
Redman 1978) was found in cases of HLA compatibility. In animals 
incompatibility of MHC antigens also favors the outcome of pregnancy (Palm 
1974, Beer 1975). However, incompatibility of non-MHC antigens can have a 
negative effect on pregnancy (Palm 1974, Dawson 1982). Perhaps the 
incompatibility of these non-MHC antigens has been responsible for the 
negative effects on pregnancy in our crossbred group. Further immunologic 
studies are required to answer this question. 
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CHAPTER 5 
GENERAL DISCUSSION 
This thesis presents an approach to develop pregnancy-induced hypertension 
(PIH) in animals by means of an immunologic model. Hypertensive pregnancy 
disorders in man may be considered a clinical expression of maladaptation in 
pregnancy. Maladaptation disease develops early in pregnancy, a long time 
before the onset of clinical signs. There is evidence that maladaptation of 
the maternal immune system to the fetal allograft is involved in the etiology 
of PIH. Increased fetomaternal MHC-antigen compatibility and non-MHC-antigen 
incompatibility may be responsible for such maladaptation, and may therefore 
lead to the disease. Fetomaternal maladaptation is possibly responsible for 
the inadequacy, or even absence, early in pregnancy of trophoblast invasion 
in the walls of the spiral arteries. Later in pregnancy it may be responsible 
for the increased platelet activation, which is even observed in mild cases 
of PIH, by formation of immune complexes. This may lead to a disturbed 
prostacyclin/thromboxane balance, which appears to be an important mechanism 
in the development of clinical signs of PIH. The elevated thromboxane 
activity in patients with PIH, resulting from enhanced platelet activity, 
leads to local vasospasm and increased platelet aggregation. This may impair 
uteroplacental blood flow, in particular in case of insufficient trophoblast 
migration, which may lead to endothelial damage and a further decrease in 
prostacyclin production. There may also be a direct effect of immune 
complexes on the production of prostacyclin by placental endothelial cells. 
The pathophysiologic pathway, that leads from maladaptation to a disturbed 
prostacyclin/thromboxane balance, and finally to the clinical manifestations 
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of PIH, is far from clear. To elucidate this problem animal experiments may 
be helpful. In this thesis the influence of parenteral heterogeneity was 
investigated with regard to signs of PIH, and of fetoplacental ischemia. In 
all pregnant Wistar rats near term lower systolic blood pressures and higher 
in vitro uterine artery 6-keto-PGFla production were found as compared with 
nonpregnant Wistar rats. After crossbreeding with Brown Norway males, 
however, the reduction in systolic blood pressure and the increase in 
6-keto-PGFla production in these animals appeared to be less than in non-
crossbred Wistar females. A negative correlation was found between the in 
vitro synthesis of 6-keto-PGFla and systolic blood pressure in pregnant 
rats with and without ticlopidine treatment, whereas in nonpregnant animals 
such a correlation was completely absent (appendix 2). This supports the 
concept that prostacyclin is involved in the regulation of blood pressure in 
pregnancy, but not in nonpregnant animals. In addition to the higher systolic 
blood pressure and lower 6-keto-PGFla production a tendency to increased 
proteinuria was observed in crossbred animals, and there were signs of 
increased fetoplacental ischemia. As compared with non-crossbred animals 
extramedullary hematopoiesis in the fetal liver and numbers of placental 
labyrinthine trophoblast and giant cells appeared to be increased in 
crossbred rats as a result of increased fetoplacental ischemia. In agreement 
with these histologic findings a lower mean fetal weight (after correction 
for litter size) was found in crossbred rats as compared with non-crossbred 
rats. The number of macroscopically observed fetal deaths, however, appeared 
to be highest in the non-crossbred group. This may perhaps be attributed to 
early fetal death and complete resorption of the fetus in crossbred animals, 
which might explain the reduced mean litter size in this group. The higher 
blood pressure, proteinuria, reduced 6-keto-PGFla production, and signs of 
fetoplacental ischemia in crossbred pregnant animals occurred spontaneously 
without intervention before or during pregnancy. 
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This picture 
between the 
fetoplacental 
6-keto-PGFla 
strongly resembles that of human PIH. The only difference 
two groups was introduced by heterogeneous paternity. As the 
unit is a major source of prostacyclin, the reduced in vitro 
production observed in crossbred rats might be explained by 
the decreased mean litter size in this group. This may explain the reduced 
decrease in blood pressure near term, but it cannot explain the increased 
proteinuria and fetoplacental ischemia in the crossbred animals. Moreover, 
the results obtained in crossbred animals with a litter size comparable with 
that found in non-crossbred animals were similar to those found in the entire 
crossbred group or in the crossbred animals with small litters. It can be 
concluded that crossbreeding Wistar females with Brown Norway males increases 
the susceptibility to developing symptoms comparable with human PIH, most 
likely because of immunologic fetomaternal maladaptation. 
The results of treatment of the crossbred females with the antiplatelet drug 
ticlopidine during pregnancy suggest that the model is appropriate for the 
study of medical intervention. In the treated animals systolic blood 
pressures and the degree of proteinuria were found to be similar to those 
observed in non-crossbred animals. In vitro synthesis of 6-keto-PGFla was 
reduced and comparable with nonpregnant values. It seems likely that 
ticlopidine decreased blood pressure by reducing thromboxane production, 
thus shifting the prostacyclin-thromboxane balance in favor of prostacyclin. 
As ticlopidine has no known direct effect on prostacyclin production, the 
observed reduction in 6-keto-PGFla production may be due to an indirect 
effect caused by other vasoactive systems, such as the renin-angiotensin or 
kallikrein-kinin systems, which are known to be closely interrelated with 
prostacyclin production. 
Histologic examination of the placentas of ticlopidine-treated crossbred rats 
showed signs of less severe hypoxia than that observed in placentas of 
untreated crossbred rats, but still more than observed in non-crossbred rats. 
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The rate of extramedullary hematopoiesis in the fetal liver of the treated 
rats was similar or even higher than that in untreated crossbred rats. Mean 
fetal weight was also lower in the treated group, but no fetal deaths were 
observed. The lack of improvement in fetal weight by ticlopidine treatment 
may be a result of the larger litter size and marginal placentation, in 
combination with a crude correction of blood pressure. In summary, the 
female Wistar rat mated with a Brown Norway male is susceptible to signs 
resembling human PIH. The model seems suitable for further studies in the 
field of the immunologic etiology and of the pathophysiologic pathways 
leading to the clinical signs of PIH. In addition, this model allows 
investigations into the effects of drug treatment of PIH on maternal and 
fetal condition. 
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SUMMARY 
In CHAPTER 1 the main objectives of this thesis are described. There is a 
need for suitable animal models to investigate the etiology and 
pathophysiologic mechanisms in pregnancy-induced hypertension (PIH). Because 
of the possible immunologic basis of PIH an animal model was investigated 
with different kinds of fetal allograft. There is some evidence that in human 
and animal pregnancy MHC-antigen incompatibility has a positive influence on 
the course and outcome of pregnancy, whereas the influence of non-MHC-antigen 
incompatibility seems to be a negative one. Compatibility for MHC-antigens 
and incompatibility for non-MHC-antigens may be associated with the 
development of PIH. In order to increase non-MHC-antigen incompatibility 
without gross changes of MHC-antigen incompatibility, Wistar female rats 
were mated with Brown Norway males. Results were compared with those obtained 
in Wistar x Wistar pregnancies. In some of the crossbred animals platelet 
aggregation was inhibited by ticlopidine in an attempt to manipulate the 
prostacyclin/thromboxane balance. 
With the use of this animal model a study was undertaken with the following 
objectives: 
-to develop PIH or a PIH-like syndrome by means of an immunologic model; 
to investigate whether or not course and outcome of pregnancy in such a 
model are comparable with that known to occur in human PIH; 
- to modulate the disease by pharmacological treatment and to investigate if 
the model could be of use in testing medication for treatment of PIH. 
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In CHAPTER 2 a review is given of the mechanisms that may be involved in the 
development of PIH in man, in spontaneous PIH-like syndromes in animals, and 
in experimental animal models of PIH. The. concept of maternal immunologic 
adaptation to the fetal allograft and the possible role of maternal 
maladaptation in the etiology of PIH are explained. 
An important step in the pathophysiology of the disease is attributed to a 
disturbed' balance in prostacyclin and thromboxane activity, perhaps in 
interaction with other vasoactive systems such as the renin-angiotensin 
system. The disturbed bilance betwe~n the vasoactive prostaglandins may be 
the result Of an immunologic process. 
Animal models are discussed in which placental ischemia was established by 
vascular occlusion, placental lesions were obtained on an immunologic basis, 
by means· of steroid hormones, or by dietary manipulation in attempts to 
induce PIH. Although some signs were obtained comparable to those found in 
human PIH, none of the reviewed animal models appears to be satisfactory. 
The possible relationship between ~arly fetomaternal mal~daptation and the 
developm~nt of PIH has not been fn~estigated in any of these models. 
In CHAPTER 3 the results of maternal and fetal outcome of crossbred 
pregnancies are presented and compared with those obtained in non-crossbred 
·pregnancies, and in crossbred pregnancies treated with ticlopidine. Blood 
pressure near term was reduced in all pregnant animals as compared with that 
in nonpregnant controls, but the decrease in blood pressure was less 
pronounced in crossbred pregnancies. Maternal weight and uterine arterial 
6-keto-PGFla production were lower in crossbred than in non-crossbred 
animals, and the severity of proteinuria was found to be increased. In the 
crossbred ~roup treated with ti~lopidine, 6-keto-PGFla production was in 
the same range as that· in nonpregnant animals, and blood pressures and 
'-.,. 
proteinuria were comparable with those in the non-crossbred group. It is 
concluded that· fetomaternal incompatibility in this model increases the 
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susceptibility of developing a pregnancy-induced hypertensive disorder. 
In CHAPTER 4 the results of morphometric quantitation of fetal livers and 
placentas with regard to morphologic signs of fetoplacental hypoxic distress 
are presented. Increased labyrinthine giant cells, trophoblast 
proliferations, and extramedullary hematopoiesis in the fetal liver, 
suggestive of placental and fetal ischemia, were found after crossbreeding. 
These changes were prevented in part in placentas of ticlopidine-treated 
animals. 
It is concluded that fetomaternal incompatibility in this model may lead to a 
disturbance of the maternal uteroplacental adaptation, and to fetal and 
placental ischemia. 
In CHAPTER 5 the results of the heterogeneity model are discussed with regard 
to the main objectives of this thesis. It is concluded that immunologic 
heterogeneity in crossbred pregnancies of Wistar females with Brown Norway 
male rats increases the susceptibility to developing signs similar to those 
observed in human PIH. The model can be used for further studies on 
immunologic factors involved in the development of PIH, but also for 
investigation of the pathophysiologic pathways which lead to PIH. In 
addition, the model allows the study of the, effects of drug treatment on 
maternal and fetal condition. 
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SAMENVATTING 
In HOOFDSTUK 1 worden de belangrijkste doelstellingen van dit proefschrift 
omschreven. Er is een behoefte aan geschikte proefdiermodellen, waarin de 
etiologie en de pathofysiologische mechanismen van zwangerschapshypertensie 
onderzocht kunnen worden. Gezien de mogelijkheid van een immunologische basis 
van zwangerschapshypertensie werd een proefdiermodel met verschillende typen 
foeten als allo-"transplantaat" bestudeerd. Er zijn aanwijzingen dat in de 
zwangerschap, zowel bij mens als dier, incompatibiliteit van MHC-antigenen 
een gunstige invloed op het verloop en het resultaat van de zwangerschap 
heeft, terwijl non-MHC-antigeen incompatibiliteit een ongunstig effect lijkt 
te hebben. Compatibiliteit voor MHC-antigenen en incompatibiliteit voor non-
MHC-antigenen is mogelijk betrokken bij het ontstaan van zwangerschaps-
hypertensie. Om een toename van de non-MHC-antigeen incompatibiliteit te 
bewerkstelligen met minimale veranderingen van de MHC-antigeen incompatibili-
teit, werden vrouwelijke Wistar ratten gedekt met Brown Norway mannetjes. De 
resultaten werden vergeleken met de resultaten zoals die verkregen waren bij 
Wistar x Wistar zwangerschappen. In verscheidene van de gekruiste dieren werd 
de plaatjesaggregatie geremd door ticlopidine in een paging de prostacycline/ 
thromboxaan balans te beinvloeden. 
Met dit proefdiermodel werden de volgende doelstellingen bestudeerd: 
- het ontwikkelen van zwangerschapshypertensie of een erop lijkend syndroom 
met behulp van een immunologisch model; 
het onderzoek of het verloop en resultaat van de zwangerschappen in zo'n 
model vergelijkbaar zijn met die zoals die bij zwangerschapshypertensie bij 
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de mens beschreven worden; 
- de farmacologische beinvloeding van het ziektebeeld en toetsing van het 
model op de mogelijke bruikbaarheid voor het uittesten van medicamenteuze 
behandeling van zwangerschapshypertensie. 
In HOOFDSTUK 2 wordt een overzicht gegeven van de mechanismen die een rol 
spelen in de ontwikkeling van zwangerschapshypertensie bij de mens, bij 
spontaan voorkomende - op zwangerschaps-hypertensie gelijkende 
ziektebeelden bij dieren en bij proefdiermodellen met zwangerschaps-
hypertensie. Het concept van maternale immunologische adaptatie ten aanzien 
van de allogene foetus en de mogelijke rol van een maternale adaptatte-
stoornis in de etiologie van zwangerschapshypertensie worden uiteengezet. 
Een belangrijke stap in de pathofysiologie van de ziekte wordt toegeschreven 
aan een verstoorde balans in de activiteit van prostacycline en thromboxaan, 
mogelijk in interactie met andere vasoactieve systemen zoals het renine-
angiotensine systeem. De verstoorde balans tussen deze vasoactieve 
prostaglandinen wordt mogelijk veroorzaakt door een immunologisch proces. 
Er worden proefdiermodellen besproken, waarbij gepoogd werd zwangerschaps-
hypertensie te induceren door middel van placentaire ischemie door vasculaire 
occlusie, dan wel werden placenta laesies verkregen op basis van een 
immunologisch mechanisme, c.q. door middel van steroid hormoontoediening of 
dieetmanipulatie. Hoewel enige gelijkenissen gevonden werden met afwijkingen 
die gezien worden bij vrouwen met zwangerschapshypertensie, bleek geen van de 
vermelde proefdiermodellen bevredigend. De mogelijke relatie tussen een reeds 
vroeg intredende foetomaternale adaptatiestoornis en de ontwikkeling van 
zwangerschapshypertensie werd in geen van deze modellen bestudeerd. 
In HOOFDSTUK 3 worden de resultaten getoond van gekruiste zwangerschappen 
voor wat. betreft het maternale en foetale beloop en vergeleken met de 
resultaten, verkregen in niet gekruiste zwangerschappen en gekruiste 
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-----------------------------------------------------
zwangerschappen, 
zwangere dieren 
vermindering in 
zwangerschappen. 
behandeld met ticlopidine. De bloeddruk a terme was in alle 
lager dan in de niet-zwangere controlegroep, maar deze 
bloeddruk was minder uitgesproken in gekruiste 
Het maternale gewicht en de 6-keto-PGFla produktie van de 
arteriae uterinae waren lager in gekruiste dan in niet gekruiste dieren en er 
was een toegenomen p~oteinurie. In de gekruiste groep die met ticlopidine 
werd behandeld, was de 6-keto-PGFla produktie vergelijkbaar met die zoals in 
niet- zwangere dieren; de bloeddruk en proteinurie waren vergelijkbaar met 
die zoals in de niet gekruiste groep. Geconcludeerd wordt dat de 
foetomaternale incompatibiliteit in dit model de vatbaarheid voor het 
ontwikkelen van een zwangerschapshypertensie verhoogt. 
In HOOFOSTUK 4 worden de resultaten van de kwantitatieve morfologie van 
foetale levers en de placenta's getoond met betrekking tot morfologische 
kenmerken van foe top 1 acenta ire hypo xi e ·' 
Een toename van labyrintaire reuscellen, trofoblast proliferaties en 
extramedullaire hematopoiese in de foetale lever, die suggestief is voor 
placentaire en foetale ischemie, werd gevonden in gekruiste zwangerschappen. 
Deze yeranderingen werden deels voorkom~n in placenta's van met ticlupidine 
behandelde dieren. De conclusie is dat foetomaternale incompatibiliteit in 
dit model tot een verstoring van de maternale uteroplacentaire vascularisatie 
leidt en tot foetale en placentaire ischemie. 
In HOOFDSTUK 5 worden de resultaten van dit heterogene zwangerschapsmodel 
bediscussieerd in het licht van de doelstellingen van dit proefschrift. 
Geconcludeerd wordt dat de immunologische heterogeniteit in gekruiste 
zwangerschappen van Wistar vrouwtjes met Brown Norway mannetjes de 
vatbaarheid tot het ontwikkelen van afwijkingen die vergelijkbaar zijn met 
die, welke in zwangerschapshypertensie bij de mens gevonden worden, verhoogt. 
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Het model kan gebruikt worden voor verdere studies naar mogelijke 
immunologische oorzaken van zwangerschapshypertensie, maar ook voor verder 
onderzoek naar de pathofysiologische mechanismen die leiden tot 
zwangerschapshypertensie. Bovendien is het model geschikt voor studies. naar 
het effect van medicamenteuze behandeling op de maternale en foetale 
conditie. 
APPENDIX 1 
W.nonpr. 6-keto-PGF1a. 
(ng/samp1e) 
--------
------------1 1.51 
2 2.34 
3 1.95 
4 4.22 
5 2.67 
6 1.90 
7 2.73 
8 1.17 
9 1.82 
10 1.12 
11 1.40 
12 1.17 
13 1.04 
= negative 
± = trace 
+ = 0.3 g/1 
++ = 1 g/1 
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syst. BP 
(mmHg) 
proteinuria 
--------
-----------105 ± 
105 ± 
110 ± 
110 ± 
115 ± 
110 
107.5 + 
120 ± 
102.5 ±j+ 
105 
107.5 ±/+ 
100 ± 
110 + 
W X W 6-keto-PGFla syst.BP proteinuria 1 itter fetal death fetal weight (ng/sample) (mmHg) size * (gram ± SO) 
------------
-------
----------- -----------
------------1 3.77 85 + 12 3.16 ± 0.27 
2 3.90 90 ± 8 4.48 ± 0.16 
3 4.42 87.5 ± 10 4. 77 ± 0.28 
4 2.08 90 ± 12 4.00 ± 0.28 
5 3.33 90 ± 12 4.37 ± 0.25 
6 1.82 90 ± 12 3.33 ± 0.19 
7 4.55 85 + 15 3.04 ± 0.25 
8 3.90 90 ± 13 3.13 ± 0.23 
9 2.03 90 ± 16 2.98 ± 0.23 
10 1.22 100 ± 12 3.11 ± 0.46 
11 3.58 85 ±/+ 11 2 2.73 ± 0.33 
12 2.73 92.5 ± 12 2.98 ± 0.21 
13 1. 90 85 ± 13 1 4.28 ± 0.30 
14 2.86 87.5 ± 12 3.20 ± 0.13 
15 5.20 92.5 + 13 1 3.12 ± 0.24 
16 4.00 85 ± 9 3 2.82 ± 0.56 
17 2.86 80 ± 12 1 3.01 ± 0.49 
18 1.61 92.5 ± 10 3.41 ± 0.15 
19 4.03 95 ++ 9 2 3.60 ± 0.16 
20 1.77 100 + 10 1 3.27 ± 0.31 
21 2.29 80 ± 12 1 3.30 ± 0.29 
22 2.44 95 ± 11 3.40 ± 0.34 
23 1.87 95 + 4 2 4.21 ± 0.85 
24 5.38 85 ± 6 •7 3.38 ± 0.10 
25 2.44 85 14 4.59 ± 0.24 
* litter size = number of fetuses alive 
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W x BN 6-keto-PGF1a syst.BP proteinuria litter fetal death fetal wei8ht 
(ng/sample) (mmHG) size * (gram ± S ) 
------------
--------
----------- ----------- ------------1 1.61 85 + 11 3.55 ± 0.13 
2 2.08 100 + 5 2 3. 77 ± 0.18 
3 4.03 90 -I± 12 3.63 ± 0.26 
4 2.44 97.5 ± 11 3.52 ± 0.24 
5 1.87 105 ± 11 3. 70 ± 0.26 
6 1.87 110 ± 11 3.67 ± 0.10 
7 2.29 85 ±/+ 10 3.65 ± 0.30 
8 2.99 95 ± 11 3.42 ± 0.15 
9 1.82 95 + 8 3.63 ± 0.17 
10 2.60 95 + 10 3.43 ± 0.15 
11 2.47 95 + 13 3.43 ± 0.45 
12 4.03 107.5 + 2 1 4.05. ± 0.64 
13 2.29 105 ± 11 3.50 ± 0.25 
14 2.73 97.5 ± 7 1 3.57 ± 0.16 
15 1.95 95 + 9 3.67 ± 0.22 
16 1.72 105 +/++ 6 3.59 ± 0.13 
17 2.42 107.5 + 10 3.81 ± 0.28 
18 1.59 105 ++ 11 3. 71 ± 0.23 
19 2.86 100 ++ 10 3.83 ± 0.23 
20 6.50 102.5 .+ 5 4.09 ± 1.18 
21 3. 77 95 ± 10 3.65 ± 0.12 
22 2.21 105 + 8 3.72 ± 0.24 
23 4.94 105 + 2 1 3. 78 ± 0.04 
24 4.62 97.5 + 12 3.81 ± 0.20 
25 1.38 95 + 9 3.57 ± 0.18 
26 1.22 105 + 6 3.66 ± 0.37 
27 1.20 100 ± 10 3.68 ± 0.32 
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28 1.61 85 ± 8 3.78 ± 0.15 
29 1.35 100 ± 9 3.22 ± 0.34 
30 1.66 95 + 6 1 3.81 ± 0.59 
31 1.04 117.5 + 3 3. 75 ± 0.26 
32 1.09 115 ± 11 3.45 ± 0.32 
33 1.74 95 ±/+ 10 3. 77 ± 0.18 
* litter size number of fetuses alive 
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APPEIILDIX 2 
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* WxW n=25 6-keto-PGF 1 ... ( n g /sample) 
• WxBN n=33 
Scatterdiagram 6-keto-PGFla I systolic blood pressure 
Wistar x Wistar and Wistar x Brown Norway 
Correlation coefficient r=-0.27 n=58 p < 0.025 
Syst. 
BI.Pr. 
(mmHg) 
110 
100 
• • 
• 
• 
90 
• 
• 
.. 
• • 
80 
• 
70~----~~-----;~-----+..------+.,----0 2 3 4 
•WxBN ticlopidine 
n=11 
6-keto-PGF1a.(ngjsample) 
Scatterdiagram 6-keto-PGFla I systolic blood pressure 
Wistar x Brown Norway Ticlopidine 
Correlation coefficient r=-0.65 n=ll p < 0.025 
90~------+.-------~------~------~------~-------+.~ 0 2 3 4 5 6 
&...;. keto-PGF1a. (ngjsample) 
Scatterdiagram 6-keto-PGFla I systolic blood pressure Wistar females 
nonpregnant. Correletion coefficient r=0.14 n=13 N.S. 
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